Psychological issues with antiretroviral drug use in HIV/AIDS

Psychological issues with antiretroviral drug use in HIV/AIDS centr mainly on issues around compliance and how this is mediated by factors such as attitudes.

Side effects of psychological interest
-

References & Bibliography


Books

 * Beal, J., & Orrick, J. J. (2006). Antiretroviral Therapy: Beal, Jeffrey (Ed); Orrick, Joanne J (Ed); Alfonso, Kimberly (Ed).
 * Brown, K. (2006). Antiretroviral Therapy in Children: Beal, Jeffrey (Ed); Orrick, Joanne J (Ed); Alfonso, Kimberly (Ed).

Papers

 * Ahdieh-Grant, L., Tarwater, P. M., Schneider, M. F., Anastos, K., Cohen, M., Khalsa, A., et al. (2005). Factors and Temporal Trends Associated With Highly Active Antiretroviral Therapy Discontinuation in the Women's Interagency HIV Study: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 38(4) Apr 2005, 500-503.
 * Aina, O. O. (2007). Virologic, immunologic and clinical outcomes in HIV-infected adults receiving antiretroviral treatment in faith-based health facilities. Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Ajithkumar, K., Iype, T., Arun, K. J., Ajitha, B. K., Aveenlal, K. P. R., & Antony, T. P. (2007). Impact of antiretroviral therapy on vocational rehabilitation: AIDS Care Vol 19(10) 2007, 1310-1312.
 * Akerele, E. O., Levin, F., Nunes, E., Brady, R., & Kleber, H. (2002). Effects of HIV triple therapy on methadone levels: The American Journal on Addictions Vol 11(4) Fal 2002, 308-314.
 * Albano, F., Giacomet, V., de Marco, G., Bruzzese, E., Starace, F., & Guarino, A. (2007). Adherence to antiretroviral therapy in children: A comparative evaluation of caregiver reports and physician judgment: AIDS Care Vol 19(6) Jul 2007, 764-766.
 * Albert, S. M., Weber, C. M., Todak, G., Polanco, C., Clouse, R., McElhiney, M., et al. (1999). An observed performance test of medication management ability in HIV: Relation to neuropsychological status and medication adherence outcomes: AIDS and Behavior Vol 3(2) Jun 1999, 121-128.
 * Alciati, A., Starace, F., Scaramelli, B., Campaniello, M., Adriani, B., Mellado, C., et al. (2001). Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? : European Psychiatry Vol 16(8) Dec 2001, 491-496.
 * Ameli, N., Bacchetti, P., Morrow, R. A., Hessol, N. A., Wilkin, T., Young, M., et al. (2006). Herpes simplex virus infection in women in the WIHS: Epidemiology and effect of antiretroviral therapy on clinical manifestations: AIDS Vol 20(7) Apr 2006, 1051-1058.
 * Amico, K. R., Harman, J. J., & Johnson, B. T. (2006). Efficacy of Antiretroviral Therapy Adherence Interventions: A Research Synthesis of Trials, 1996 to 2004: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 41(3) Mar 2006, 285-297.
 * Amico, K. R., Konkle-Parker, D. J., Cornman, D. H., Barta, W. D., Ferrer, R., Norton, W. E., et al. (2007). Reasons for ART non-adherence in the Deep South: Adherence needs of a sample of HIV-positive patients in Mississippi: AIDS Care Vol 19(10) 2007, 1210-1218.
 * Amico, K. R., Toro-Alfonso, J., & Fisher, J. D. (2005). An empirical test of the Information, Motivation and Behavioral Skills model of antiretroviral therapy adherence: AIDS Care Vol 17(6) Aug 2005, 661-673.
 * Ammassari, A., Antinori, A., Aloisi, M. S., Trotta, M. P., Murri, R., Bartoli, L., et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 45(5) Oct 2004, 394-402.
 * Ananworanich, J., Pumpradit, W., Apateerapong, W., Siangphoe, U., Saenawat, S., Phanuphak, P., et al. (2008). Preference for CD4-guided versus continuous HAART in Thailand: AIDS Care Vol 20(3) Mar 2008, 327-330.
 * Ances, B. M., Letendre, S. L., Alexander, T., & Ellis, R. J. (2008). Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders: International Review of Psychiatry Vol 20(1) Feb 2008, 89-93.
 * Ances, B. M., Roc, A. C., Wang, J., Korczykowski, M., Okawa, J., Stern, J., et al. (2006). Caudate blood flow and volume are reduced in HIV-super(+) neurocognitively impaired patients: Neurology Vol 66(6) Mar 2006, 862-866.
 * Antela, A. (2001). Access to antiretroviral therapy in HIV-infected injection drug users: AIDS Vol 15(13) Sep 2001, 1727-1728.
 * Anthony, I. C., & Bell, J. E. (2008). The neuropathology of HIV/AIDS: International Review of Psychiatry Vol 20(1) Feb 2008, 15-24.
 * Arendt, G., Giesen, H.-J. V., Hefter, H., & Theisen, A. (2001). Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection: AIDS Vol 15(4) Mar 2001, 493-500.
 * Arnsten, J. H., Li, X., Mizuno, Y., Knowlton, A. R., Gourevitch, M. N., Handley, K., et al. (2007). Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(Suppl 2) Nov 2007, S64-S71.
 * Arribas, J. R., Pozniak, A. L., Gallant, J. E., DeJesus, E., Gazzard, B., Campo, R. E., et al. (2008). Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(1) Jan 2008, 74-78.
 * Aspeling, H. E., & van Wyk, N. C. (2008). Factors associated with adherence to antiretroviral therapy for the treatment of HIV-infected women attending an urban care facility: International Journal of Nursing Practice Vol 14(1) Feb 2008, 3-10.
 * Atkinson, J. S., Schonnesson, L. N., Williams, M. L., & Timpson, S. C. (2008). Associations among correlates of schedule adherence to antiretroviral therapy (ART): A path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection: AIDS Care Vol 20(2) Feb 2008, 260-269.
 * Authier, F. J., & Gherardi, R. K. (2006). Muscular complications of human immunodeficiency virus (HIV) infection in the era of effective anti-retroviral therapy: Revue Neurologique Vol 162(1) Jan 2006, 71-81.
 * Back, D. J., Burger, D. M., Flexner, C. W., & Gerber, J. G. (2005). The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors: Implications for Once-Daily Dosing: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 39(Suppl1) Aug 2005, S1-S23.
 * Bakeera-Kitaka, S., Nabukeera-Barungi, N., Nostlinger, C., Addy, K., & Colebunders, R. (2008). Sexual risk reduction needs of adolescents living with HIV in a clinical care setting: AIDS Care Vol 20(4) Apr 2008, 426-433.
 * Bangsberg, D. R., Acosta, E. P., Gupta, R., Guzman, D., Riley, E. D., Harrigan, P. R., et al. (2006). Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness: AIDS Vol 20(2) Jan 2006, 223-231.
 * Bangsberg, D. R., Bronstone, A., & Hofmann, R. (2002). A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy: AIDS Care Vol 14(1) Feb 2002, 3-15.
 * Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Chesney, M., & Moss, A. (2001). Comparing objective measures of adherence to HIV antiretroviral therapy: Electronic medication monitors and unannounced pill counts: AIDS and Behavior Vol 5(3) Sep 2001, 275-281.
 * Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population: AIDS Vol 14(4) Mar 2000, 357-366.
 * Barclay, T. R., Hinkin, C. H., Castellon, S. A., Mason, K. I., Reinhard, M. J., Marion, S. D., et al. (2007). Age-associated predictors of medication adherence in HIV-positive adults: Health beliefs, self-efficacy, and neurocognitive status: Health Psychology Vol 26(1) Jan 2007, 40-49.
 * Barreiro, P., Soriano, V., Blanco, F., Casimiro, C., Jose de la Cruz, J., & Gonzalez-Lahoz, J. (2000). Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy: AIDS Vol 14(7) May 2000, 807-812.
 * Battaglioli-DeNero, A. M. (2007). Strategies for Improving Patient Adherence to Therapy and Long-Term Patient Outcomes: JANAC: Journal of the Association of Nurses in AIDS Care Vol 18(1, Suppl) Jan-Feb 2007, S17-S22.
 * Batterham, P., Rice, E., & Rotheram-Borus, M. J. (2005). Predictors of serostatus disclosure to partners among young people living with HIV in the pre- and post-HAART eras: AIDS and Behavior Vol 9(3) Sep 2005, 281-287.
 * Bauer, L. O., Ceballos, N. A., Shanley, J. D., & Wolfson, L. I. (2005). Sensorimotor Dysfunction in HIV/AIDS: Effects of Antiretroviral Treatment and Comorbid Psychiatric Disorders: AIDS Vol 19(5) Mar 2005, 495-502.
 * Bauer, L. O., & Shanley, J. D. (2006). ASPD Blunts the Effects of HIV and Antiretroviral Treatment on Event-Related Brain Potentials: Neuropsychobiology Vol 53(1) Feb 2006, 17-25.
 * Bautista-Arredondo, S., Mane, A., & Bertozzi, S. M. (2006). Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: Lessons from Mexico: AIDS Vol 20(1) Jan 2006, 101-109.
 * Bell, D. J., Kapitao, Y., Sikwese, R., van Oosterhout, J. J., & Lalloo, D. G. (2007). Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 45(5) Aug 2007, 560-563.
 * Berg, K. M., & Arnsten, J. H. (2006). Practical and Conceptual Challenges in Measuring Antiretroviral Adherence: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S79-S87.
 * Berger, J. R., & Nath, A. (2000). Remedies for HIV-associated peripheral neuropathy: Neurology Vol 54(11) Jun 2000, 2037-2038.
 * Berkeley, J. L., Nath, A., & Pardo, C. A. (2008). Fatal immune reconstitution inflammatory syndrome with human immunodeficiency virus infection and Candida meningitis: Case report and review of the literature: Journal of Neurovirology Vol 14(3) Jun 2008, 267-276.
 * Bialer, P. A., Kato, K. S., & Latoussakis, V. (2006). Psychotropic Drug Interactions with Antiretroviral Medications. Philadelphia, PA: Lippincott Williams & Wilkins Publishers.
 * Bikaako-Kajura, W., Luyirika, E., Purcell, D. W., Downing, J., Kaharuza, F., Mermin, J., et al. (2006). Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda: AIDS and Behavior Vol 10(Suppl1) July 2006, S85-S93.
 * Biscione, F. M. (2007). Regarding "Persistence of neuropsycholgic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: Prevalence and risk factors." JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(4) Dec 2007, 510.
 * Blanes, M., Boix, V., Belinchon, I., & Portilla, J. (2008). Angiolipomas, a rare manifestation of HIV-associated lipodystrophy: AIDS Vol 22(4) Feb 2008, 552-554.
 * Boarts, J. M., Bogart, L. M., Tabak, M. A., Armelie, A. P., & Delahanty, D. L. (2008). Relationship of race-, sexual orientation-, and HIV-related discrimination with adherence to HIV treatment: A pilot study: Journal of Behavioral Medicine Vol 31(5) Oct 2008, 445-451.
 * Bouhnik, A. D., Moatti, J. P., Vlahov, D., Gallais, H., Dellamonica, P., & Obadia, Y. (2002). Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users: Journal of Epidemiology & Community Health Vol 56(5) May 2002, 349-353.
 * Bova, C. A., Fennie, K. P., Knafl, G. J., Dieckhaus, K. D., Watrous, E., & Williams, A. B. (2005). Use of Electronic Monitoring Devices to Measure Antiretroviral Adherence: Practical Considerations: AIDS and Behavior Vol 9(1) Mar 2005, 103-110.
 * Braithwaite, R. S., Kozal, M. J., Chang, C. C. H., Roberts, M. S., Fultz, S. L., Goetz, M. B., et al. (2007). Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies: AIDS Vol 21(12) Jul 2007, 1579-1589.
 * Brief, D. J., Bollinger, A. R., Vielhauer, M. J., Berger-Greenstein, J. A., Morgan, E. E., Brady, S. M., et al. (2004). Understanding the interface of HIV, trauma, post-traumatic stress disorder, and substance use and its implications for health outcomes: AIDS Care Vol 16(Suppl1) 2004, S97-S120.
 * Brouilette, M.-J., & Routy, J.-P. (2007). Abacavir sulfate and mania in HIV: American Journal of Psychiatry Vol 164(6) Jun 2007, 979-980.
 * Brouillette, M.-J., Chouinard, G., & Lalonde, R. (1994). Didanosine-induced mania in HIV infection: American Journal of Psychiatry Vol 151(12) Dec 1994, 1839-1840.
 * Brouwers, P., Hendricks, M., Lietzau, J. A., Pluda, J. M., & et al. (1997). Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: A comparison of simultaneous and alternating regimens: AIDS Vol 11(1) Jan 1997, 59-66.
 * Brown, D. M., Thorne, J. E., Foster, G. L., Duncan, J. L., Brune, L. M., Munana, A., et al. (2006). Factors affecting attrition in a longitudinal study of patients with AIDS: AIDS Care Vol 18(7) Oct 2006, 821-829.
 * Brown, T. T., & Qaqish, R. B. (2006). Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review: AIDS Vol 20(17) Nov 2006, 2165-2174.
 * Bucciardini, R., Murri, R., Guarinieri, M., Starace, F., Martini, M., Vatrella, A., et al. (2006). ISSQoL: A new questionnaire for evaluating the quality of life of people living with HIV in the HAART era: Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation Vol 15(3) Apr 2006, 377-390.
 * Bucciardini, R., Wu, A. W., Floridia, M., Fragola, V., Ricciardulli, D., Tomino, C., et al. (2000). Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients: AIDS Vol 14(16) Nov 2000, 2567-2574.
 * Burgoyne, R. W., Rourke, S. B., Behrens, D. M., & Salit, I. E. (2004). Long-Term Quality-of-Life Outcomes Among Adults Living with HIV in the HAART Era: The Interplay of Changes in Clinical Factors and Symptom Profile: AIDS and Behavior Vol 8(2) Jun 2004, 151-163.
 * Burman, W. J., Grund, B., Roediger, M. P., Friedland, G., Darbyshire, J., & Wu, A. W. (2008). The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(2) Feb 2008, 185-193.
 * Byrne, M. W., & Honig, J. (2006). Health-Related Quality of Life of HIV-Infected Children on Complex Antiretroviral Therapy at Home: JANAC: Journal of the Association of Nurses in AIDS Care Vol 17(2) Mar-Apr 2006, 27-35.
 * C. Harry, T., Matthews, M., & Salvary, I. (2000). Indinavir use: Associated reversible hair loss and mood disturbance: International Journal of STD & AIDS Vol 11(7) Jul 2000, 474-476.
 * Carrico, A. W., Johnson, M. O., Moskowitz, J. T., Neilands, T. B., Morin, S. F., Charlebois, E. D., et al. (2007). Affect regulation, stimulant use, and viral load among HIV-positive persons on anti-retroviral therapy: Psychosomatic Medicine Vol 69(8) Oct 2007, 785-792.
 * Carrieri, M. P., Chesney, M. A., Spire, B., Loundou, A., Sobel, A., Lepeu, G., et al. (2003). Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users: International Journal of Behavioral Medicine Vol 10(1) Mar 2003, 1-14.
 * Carrieri, M. P., Vlahov, D., Dellamonica, P., Gallais, H., Lepeu, G., Spire, B., et al. (2000). Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART: Drug and Alcohol Dependence Vol 60(1) Jul 2000, 51-54.
 * Carries, S., Muller, F., Muller, F. J., Morroni, C., & Wilson, D. (2007). Characteristics, treatment, and antiretroviral prophylaxis adherence of South African rape survivors: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(1) Sep 2007, 68-71.
 * Casseb, J., Fonseca, L. A. M., Veiga, A. P. R., de Almeida, A., Bueno, A., Ferez, A. C., et al. (2003). AIDS Incidence and Mortality in a Hospital-Based Cohort of HIV-1-Seropositive Patients Receiving Highly Active Antiretroviral Therapy in Sao Paulo, Brazil: AIDS Patient Care and STDs Vol 17(9) Sep 2003, 447-452.
 * Castilla, J., del Romero, J., Hernando, V., Marincovich, B., Garcia, S., & Rodriguez, C. (2005). Effectiveness of Highly Active Antiretroviral Therapy in Reducing Heterosexual Transmission of HIV: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 40(1) Sep 2005, 96-101.
 * Castillo, E., Palepu, A., Beardsell, A., Akagi, L., Yip, B., Montaner, J. S. G., et al. (2004). Outpatient pharmacy care and HIV viral load response among patients on HAART: AIDS Care Vol 16(4) Apr 2004, 446-457.
 * Catz, S. L., Kalichman, S. C., Benotsch, E. G., Miller, J., & Suarez, T. (2001). Anticipated psychological impact of receiving medical feedback about HIV treatment outcomes: AIDS Care Vol 13(5) Oct 2001, 631-635.
 * Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., & McAuliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease: Health Psychology Vol 19(2) Mar 2000, 124-133.
 * Cederfjall, C., Langius-Eklof, A., Lidman, K., & Wredling, R. (2002). Self-reported adherence to antiretroviral treatment and degree of sense of coherence in a group of HIV-infected patients: AIDS Patient Care and STDs Vol 16(12) Dec 2002, 609-616.
 * Celentano, D. D., Galai, N., Sethi, A. K., Shah, N. G., Strathdee, S. A., Vlahov, D., et al. (2001). Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users: AIDS Vol 15(13) Sep 2001, 1707-1715.
 * Chang, L., Ernst, T., Leonido-Yee, M., Witt, M., Speck, O., Walot, I., et al. (1999). Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia: Neurology Vol 53(4) Sep 1999, 782-789.
 * Chen, S. Y. S. (2007). A novel use of AIDS surveillance data to assess the impact of highly active antiretroviral therapy on death, 1996--2004. Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Chesney, M. (2003). Adherence to HAART regimens: AIDS Patient Care and STDs Vol 17(4) Apr 2003, 169-177.
 * Chesney, M. A. (2006). The Elusive Gold Standard: Future Perspectives for HIV Adherence Assessment and Intervention: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S149-S155.
 * Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments: AIDS Care Vol 12(3) Jun 2000, 255-266.
 * Chi, B. H., Chansa, K., Gardner, M. O., Sangi-Haghpeykar, H., Goldenberg, R. L., Sinkala, M., et al. (2004). Perceptions toward HIV, HIV screening, and the use of antiretroviral medications: A survey of maternity-based health care providers in Zambia: International Journal of STD & AIDS Vol 15(10) Oct 2004, 685-690.
 * Chi, B. H., Wang, L., Read, J. S., Sheriff, M., Fiscus, S., Brown, E. R., et al. (2005). Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024: AIDS Vol 19(16) Nov 2005, 1857-1864.
 * Chin-Hong, P. V., Deeks, S. G., Liegler, T., Hagos, E., Krone, M. R., Grant, R. M., et al. (2005). High-Risk Sexual Behavior in Adults With Genotypically Proven Antiretroviral-Resistant HIV Infection: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 40(4) Dec 2005, 463-471.
 * Christo, P. P., Greco, D. B., Aleixo, A. W., & Livramento, J. A. (2005). Niveis de RNA do HIV-1 no liquido cefalorraqueano e plasma e sua correlacao com doenca neurologica oportunistica em um hospital referencia em AIDS: Arquivos de Neuro-Psiquiatria Vol 63(4) Dec 2005, 907-913.
 * Cocohoba, J., Wang, Q. J., Cox, C., Gange, S. J., Cohen, M., Glesby, M., et al. (2008). Consistency of initial antiretroviral therapy with HIV treatment guidelines in a US cohort of HIV-infected Women: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(3) Mar 2008, 377-383.
 * Cohen, C., Revicki, D. A., Nabulsi, A., Sarocco, P. W., Jiang, P., & Advanced, H. I. V. D. R. S. G. (1998). A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease: AIDS Vol 12(12) Aug 1998, 1495-1502.
 * Cohen, R. A., Boland, R., Paul, R., Tashima, K. T., Schoenbaum, E. E., Celentano, D. D., et al. (2001). Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women: AIDS Vol 15(3) Feb 2001, 341-345.
 * Cohn, S. E., Umbleja, T., Mrus, J., Bardeguez, A. D., Andersen, J. W., & Chesney, M. A. (2008). Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: Adherence analysis A5084: AIDS Patient Care and STDs Vol 22(1) Jan 2008, 29-40.
 * Colebunders, R., Verdonck, K., Nachega, J., & Kothari, P. (2000). Impact of new developments in antiretroviral treatment on AIDS prevention and care in resource-poor countries: AIDS Patient Care and STDs Vol 14(5) May 2000, 251-257.
 * Collazos, J., Mayo, J., Maretinez, E., & Ibarra, S. (2002). Association between sexual disturbances and sexual hormones with specific antiretroviral drugs: AIDS Vol 16(9) Jun 2002, 1294-1295.
 * Collings, S. J. (2005). Provision of Antiretroviral Prophylaxis to Child Rape Victims in South Africa: HIV Status and Delayed Reporting: Psychological Reports Vol 96(1) Feb 2005, 17-18.
 * Conant, M. A., & Belasco, K. T. (2006). Dermatological Manifestations of HIV/AIDS: Beal, Jeffrey (Ed); Orrick, Joanne J (Ed); Alfonso, Kimberly (Ed).
 * Cook, J. A., Grey, D., Burke-Miller, J., Cohen, M. H., Anastos, K., Gandhi, M., et al. (2006). Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women: AIDS Care Vol 18(2) Feb 2006, 93-100.
 * Cook, J. A., Grey, D. D., Burke-Miller, J. K., Cohen, M. H., Vlahov, D., Kapadia, F., et al. (2007). Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women: Drug and Alcohol Dependence Vol 89(1) Jun 2007, 74-81.
 * Cooper, D., Harries, J., Myer, L., Orner, P., & Bracken, H. (2007). "Life is still going on": Reproductive intentions among HIV-positive women and men in South Africa: Social Science & Medicine Vol 65(2) Jul 2007, 274-283
 * Corless, I. B., Kirksey, K. M., Kemppainen, J., Nicholas, P. K., McGibbon, C., Davis, S. M., et al. (2005). Lipodystrophy-Associated Symptoms and Medication Adherence in HIV/AIDS: AIDS Patient Care and STDs Vol 19(9) Sep 2005, 577-586.
 * Crane, J. R., Perlman, S., Meredith, K. L., Jeffe, D. B., Fraser, V. J., Lucas, A. M., et al. (2000). Women with HIV: Conflicts and synergy of prayer within the realm of medical care: AIDS Education and Prevention Vol 12(6) Dec 2000, 532-543.
 * Cysique, L. A. J., Maruff, P., & Brew, B. J. (2006). Variable benefit in neuropsychologieal function in HIV-infected HAART-treated patients: Neurology Vol 66(9) May 2006, 1447-1450.
 * Dalal, R. P., MacPhail, C., Mqhayi, M., Wing, J., Feldman, C., Chersich, M. F., et al. (2008). Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(1) Jan 2008, 101-107.
 * Daniel, V., Naujokat, C., Sadeghi, M., Zimmermann, R., Huth-Kuhne, A., & Opelz, G. (2008). Normal or even increased dendritic cell and peripheral blood lymphocyte subsets with regulatory phenotype in clinically stable long-term HIV-infected patients with hemophilia on highly active antiretroviral therapy: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(1) Jan 2008, 1-15.
 * Das, S. K., Pareek, A., Mathur, D. S., Wanchu, A., Srivastava, R., Agarwal, G. G., et al. (2007). Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: A randomized, double-blind, placebo controlled clinical trial: An Indian experience: Current Medical Research and Opinion Vol 23(9) Sep 2007, 2227-2234.
 * Davies, G., Koenig, L. J., Stratford, D., Palmore, M., Bush, T., Golde, M., et al. (2006). Overview and implementation of an intervention to prevent adherence failure among HIV-infected adults initiating antiretroviral therapy: Lessons learned from Project HEART: AIDS Care Vol 18(8) Nov 2006, 895-903.
 * Davis, M., Frankis, J., & Flowers, P. (2006). Uncertainty and 'technological horizon' in qualitative interviews about HIV treatment: Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine Vol 10(3) Jul 2006, 323-344.
 * Day, J. H., Miyamura, K., Grant, A. D., Leeuw, A., Munsamy, J., Baggaley, R., et al. (2003). Attitudes to HIV voluntary counselling and testing among mineworkers in South Africa: Will availability of antiretroviral therapy encourage testing? : AIDS Care Vol 15(5) Oct 2003, 665-672.
 * de Jong, B. C., Prentiss, D., McFarland, W., Machekano, R., & Israelski, D. M. (2005). Marijuana Use and Its Association With Adherence to Antiretroviral Therapy Among HIV-Infected Persons With Moderate to Severe Nausea: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 38(1) Jan 2005, 43-46.
 * De Ronchi, D., Lazzari, C., Rucci, P., & Cangialosi, A. (1996). Neurocognitive effects of zidovudine and 2',3'-dideoxyinosine during the treatment of asymptomatic and symptomatic HIV-1 seropositive patients. Comparison with non-treated patients: Human Psychopharmacology: Clinical and Experimental Vol 11(5) Sep-Oct 1996, 415-420.
 * Delobel, P., Sandres-Saune, K., Cazabat, M., L'Faqihi, F.-E., Aquilina, C., Obadia, M., et al. (2005). Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART: AIDS Vol 19(16) Nov 2005, 1739-1750.
 * Demeester, R., Omes, C., Karasi, J. C., Schneider, S., Mugabo, J., Maliboli, M. J., et al. (2005). Adherence to First-Line Antiretroviral Regimens in Rwanda: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 40(1) Sep 2005, 113-114.
 * Demmer, C. (2002). Impact of improved treatments on perceptions about HIV and safer sex among inner-city HIV-infected men and women: Journal of Community Health: The Publication for Health Promotion and Disease Prevention Vol 27(1) Feb 2002, 63-73.
 * Demmer, C. (2003). Attitudes toward HIV protease inhibitors and medication adherence in an inner city HIV population: AIDS Patient Care and STDs Vol 17(11) Nov 2003, 575-580.
 * DeSilva, K. E., Le Flore, D. B., Marston, B. J., & Rimland, D. (2001). Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine: AIDS Vol 15(10) Jul 2001, 1281-1285.
 * Deutsch, R., Ellis, R. J., McCutchan, A., Marcotte, T. D., Letendre, S., & Grant, I. (2001). AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy: AIDS Vol 15(14) Sep 2001, 1898-1899.
 * Diabate, S., Alary, M., & Koffi, C. K. (2007). Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d'Ivoire: AIDS Vol 21(13) Aug 2007, 1799-1803.
 * Diamond, C., Richardson, J. L., Milam, J., Stoyanoff, S., McCutchan, J. A., Kemper, C., et al. (2005). Use of and Adherence to Antiretroviral Therapy Is Associated With Decreased Sexual Risk Behavior in HIV Clinic Patients: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 39(2) Jun 2005, 211-218.
 * Dickerson, F. B., Boronow, J. J., Stallings, C. R., Origoni, A. E., & Yolken, R. H. (2003). Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia: American Journal of Psychiatry Vol 160(12) Dec 2003, 2234-2236.
 * Dieckhaus, K. D., & Odesina, V. (2007). Outcomes of a multifaceted medication adherence intervention for HIV-positive patients: AIDS Patient Care and STDs Vol 21(2) Feb 2007, 81-91.
 * Dieperink, E., Leskela, J., Dieperink, M. E., Evans, B., Thuras, P., & Ho, S. B. (2008). The effect of pegylated interferon-alpha -sub(2b) and Ribavirin on posttraumatic stress disorder symptoms: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 49(3) May-Jun 2008, 225-229.
 * Diiorio, C., McCarty, F., Resnicow, K., Holstad, M. M., Soet, J., Yeager, K., et al. (2008). Using motivational interviewing to promote adherence to antiretroviral medications: A randomized controlled study: AIDS Care Vol 20(3) Mar 2008, 273-283.
 * DiIorio, C., Resnicow, K., McDonnell, M., Soet, J., McCarty, F., & Yeager, K. (2003). Using Motivational Interviewing to Promote Adherence to Antiretroviral Medications: A Pilot Study: JANAC: Journal of the Association of Nurses in AIDS Care Vol 14(2) Mar-Apr 2003, 52-62.
 * Diomande, F. V. K., Bissagnene, E., Nkengasong, J. N., Maurice, C., Monga, B., Laga, M., et al. (2003). The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: Empirical data from Cote d'Ivoire's Drug Access Initiative: AIDS Vol 17(Suppl3) Jul 2003, S87-S93.
 * Domek, G. J. (2006). Social consequences of antiretroviral therapy: Preparing for the unexpected futures of HIV-positive children: Lancet Vol 367(9519) Apr 2006, 1367-1369.
 * Dore, G. J., McDonald, A., Li, Y., Kaldor, J. M., & Brew, B. J. (2003). Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy: AIDS Vol 17(10) Jul 2003, 1539-1545.
 * Dorz, S., Lazzarini, L., Cattelan, A., Meneghetti, F., Novara, C., Concia, E., et al. (2003). Evaluation of adherence to antiretroviral therapy in Italian HIV patients: AIDS Patient Care and STDs Vol 17(1) Jan 2003, 33-41.
 * Douglas, S. D. (2005). Hepatitis C, depressive symptoms, viral load, and therapy: Interactions and reactions: Brain, Behavior, and Immunity Vol 19(1) Jan 2005, 20-22.
 * Doxanakis, A., Read, T., Levy, R., Mijch, A., & Fairley, C. K. (2006). Cohort analysis of two multidisciplined adherence intervention programmes for patients on antiretroviral therapy: International Journal of STD & AIDS Vol 17(4) Apr 2006, 257-259.
 * Drogoul-Vey, M. P., Marimoutou, C., Robaglia-Schlupp, A., Beerli, M., Gastaut, J. A., Cau, P., et al. (2007). Determinants and evolution of squamous intraepithelial lesions in HIV-infected women, 1991-2004: AIDS Care Vol 19(8) Sep 2007, 1052-1057.
 * Dronda, F., Zamora, J., Moreno, S., Moreno, A., Casado, J. L., Muriel, A., et al. (2004). CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: The role of intravenous drug use: AIDS Vol 18(16) Nov 2004, 2210-2212.
 * Duggan, J., Peterson, W. S., Schutz, M., Khuder, S., & Charkraborty, J. (2001). Use of complementary and alternative therapies in HIV-infected patients: AIDS Patient Care and STDs Vol 15(3) Mar 2001, 159-167.
 * Dukers, N. H. T. M., Goudsmit, J., de Wit, J. B. F., Prins, M., Weverling, G.-J., & Coutinho, R. A. (2001). Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection: AIDS Vol 15(3) Feb 2001, 369-378.
 * Duran, S., Savees, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., et al. (2001). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy: AIDS Vol 15(18) Dec 2001, 2441-2444.
 * Duran, S., Solas, C., Spire, B., Carrieri, M. P., Fuzibet, J.-G., Costagliola, D., et al. (2001). 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study: AIDS Vol 15(8) May 2001, 1075-1077.
 * Durante, A. J., Bova, C. A., Fennie, K. P., Danvers, K. A., Holness, D. R., Burgess, J. D., et al. (2003). Home-based study of anti-HIV drug regimen adherence among HIV-infected women: Feasibility and preliminary results: AIDS Care Vol 15(1) Feb 2003, 103-115.
 * Dursun, S. M., Handley, S. L., & Freeman, S. (1993). Anti-AIDS agents AZT and TIBO (R 82913) reduce 5-HT-sub-2 receptor-mediated DOI-head-shakes in mice: Journal of Psychopharmacology Vol 7(2) 1993, 215-216.
 * Eboko, F. (2005). Law against morality? Access to anti-AIDS drugs in Africa: International Social Science Journal Vol 57(186) Dec 2005, 715-724.
 * Egger, M. (2003). Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies: Lancet Vol 362(9385) Aug 2003, 679-686.
 * Elise, A., France, A. M., Louise, W. M., Bata, D., Francois, R., Roger, S., et al. (2005). Assessment of Adherence to Highly Active Antiretroviral Therapy in a Cohort of African HIV-lnfected Children in Abidjan, Cote d'Ivoire: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 40(4) Dec 2005, 498-500.
 * Enriquez, M., Gore, P. A., Jr., O'Connor, M. C., & McKinsey, D. S. (2004). Assessment of Readiness for Adherence by HIV-Positive Males Who Had Previously Failed Treatment: JANAC: Journal of the Association of Nurses in AIDS Care Vol 15(1) Jan-Feb 2004, 42-49.
 * Erger, J., Grusky, O., Mann, T., & Marelich, W. (2000). HIV healthcare provider-patient interaction: Observations on the process of providing antiretroviral treatment: AIDS Patient Care and STDs Vol 14(5) May 2000, 259-268.
 * Eshleman, S. H., Husnik, M., Hudelson, S., Donnell, D., Huang, Y., Huang, W., et al. (2007). Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection: AIDS Vol 21(9) May 2007, 1165-1174.
 * Estes, K. E., Busse, K. H., & Penzak, S. R. (2007). Pharmacogenetic considerations in the management of HIV infection: Journal of Pharmacy Practice Vol 20(3) Jun 2007, 234-245.
 * Evans, S., Ferrando, S. J., Rabkin, J. G., & Fishman, B. (2000). Health locus of control, distress, and utilization of protease inhibitors among HIV-positive men: Journal of Psychosomatic Research Vol 49(2) Aug 2000, 157-162.
 * Ezzy, D. M., Bartos, M. R., de Visser, R. O., & Rosenthal, D. A. (1998). Antiretroviral uptake in Australia: Medical, attitudinal and cultural correlates: International Journal of STD & AIDS Vol 9(10) Oct 1998, 579-586.
 * Farber, E. W., & McDaniel, J. S. (1999). Assessment and psychotherapy practice implications of new combination antiviral therapies for HIV disease: Professional Psychology: Research and Practice Vol 30(2) Apr 1999, 173-179.
 * Ferguson, T. F., Stewart, K. E., Funkhouser, E., Tolson, J., Westfall, A. O., & Saag, M. S. (2002). Patient-perceived barriers to antiretroviral adherence: Associations with race: AIDS Care Vol 14(5) Oct 2002, 607-617.
 * Fernandas, A. P. M., Sanches, R. S., Mill, J., Lucy, D., Palha, P. F., & Dairi, M. C. B. (2007). Lipodystrophy syndrome associated with antiretroviral therapy in HIV patients: Considerations for psychosocial aspects: Revista Latino-Americana de Enfermagem Vol 15(5) Sep-Oct 2007, 1041-1045.
 * Ferrando, S. (1998). Behavioral research on AIDS--Protease inhibitors and the new millennium: Comment on Kelly, Otto-Salaj, Sikkema, Pinkerton, and Bloom (1998): Health Psychology Vol 17(4) Jul 1998, 307-309.
 * Ferrando, S., van Gorp, W., McElhiney, M., Goggin, K., Sewell, M., & Rabkin, J. (1998). Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function: AIDS Vol 12(8) May 1998, F65-F70.
 * Ferrando, S. J., & Nims, C. (2006). HIV-associated mania treated with electroconvulsive therapy and highly-active antiretroviral therapy: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 47(2) Mar-Apr 2006, 170-174.
 * Ferrando, S. J., Rabkin, J. G., van Gorp, W., & McElhiney, M. (2003). Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection: Journal of Neuropsychiatry & Clinical Neurosciences Vol 15(2) Spr 2003, 208-214.
 * Fielden, S. J., Rusch, M. L. A., Levy, A. R., Yip, B., Wood, E., Harrigan, R. P., et al. (2008). Predicting hospitalization among HIV-infected antiretroviral naive patients starting HAART: Determining clinical markers and exploring social pathways: AIDS Care Vol 20(3) Mar 2008, 297-303.
 * Fieno, J. V. (2008). Costing adult male circumcision in high HIV prevalence, low circumcision rate countries: AIDS Care Vol 20(5) May 2008, 515-520.
 * Fisher, J. D., Fisher, W. A., Amico, K. R., & Harman, J. J. (2006). An information-motivation-behavioral skills model of adherence to antiretroviral therapy: Health Psychology Vol 25(4) Jul 2006, 462-473.
 * Florindo, A. A., de Oliveira Latorre, M. d. R. D., Jaime, P. C., & Segurado, A. A. C. (2007). Leisure time physical activity prevents accumulation of central fat in HIV/AIDS subjects on highly active antiretroviral therapy: International Journal of STD & AIDS Vol 18(10) Oct 2007, 692-696.
 * Fogarty, L., Roter, D., Larson, S., Burke, J., Gillespie, J., & Levy, R. (2002). Patient adherence to HIV medication regimens: A review of published and abstract reports: Patient Education and Counseling Vol 46(2) Feb 2002, 93-108.
 * Foster, G. R. (2008). Injecting drug users with chronic hepatitis C: Should they be offered antiviral therapy? : Addiction Vol 103(9) Sep 2008, 1412-1413.
 * Foster, R., Taylor, C., & Everall, I. P. (2004). More on abacavir-induced neuropsychiatric reactions: AIDS Vol 18(18) Dec 2004, 2449.
 * Fowler, C. L. (2007). Illness representations, coping, and quality of life in patients with hepatitis C undergoing antiviral therapy. Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Fraenkel, L., McGraw, S., Wongcharatrawee, S., & Garcia-Tsao, G. (2006). Patients' experiences related to anti-viral treatment for hepatitis C: Patient Education and Counseling Vol 62(1) Jul 2006, 148-155.
 * Freedberg, K. A., Hirschhorn, L. R., Schackman, B. R., Wolf, L. L., Martin, L. A., Weinstein, M. C., et al. (2006). Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S113-S118.
 * Freeman, R. C., Williams, M. L., & Saunders, L. A. (2000). Comparison of antiretroviral medical name recall and antiretroviral names on prescription container labels in a sample of drug users being treated for HIV/AIDS: AIDS Patient Care and STDs Vol 14(8) Aug 2000, 401-404.
 * French, T., Weiss, L., Waters, M., Tesoriero, J., Finkelstein, R., & Agins, B. (2005). Correlation of a Brief Perceived Stress Measure With Nonadherence to Antiretroviral Therapy Over Time: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 38(5) Apr 2005, 590-597.
 * Friedman, S. R., Wainberg, M. A., & Drucker, E. (1998). Therapeutic ethics and communities at risk in the presence of potential mutation to resistant strains to HIV antiviral medications: AIDS Vol 12(16) Nov 1998, 2089-2093.
 * Fumaz, C. R., Munoz-Moreno, J. A., Molto, J., Negredo, E., Ferrer, J. M., Sirera, G., et al. (2005). Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 38(5) Apr 2005, 560-565.
 * Furler, M. D., Einarson, T. R., Walmsley, S., Millson, M., & Bendayan, R. (2006). Longitudinal Trends in Antiretroviral Use in a Cohort of Men and Women in Ontario, Canada: AIDS Patient Care and STDs Vol 20(4) Apr 2006, 245-257.
 * Gardner, E. M., Burman, W. J., Maravi, M. E., & Davidson, A. J. (2006). Durability of Adherence to Antiretroviral Therapy on Initial and Subsequent Regimens: AIDS Patient Care and STDs Vol 20(9) Sep 2006, 628-636.
 * Gardner, E. M., Sharma, S., Peng, G., Hullsiek, K. H., Burman, W. J., MacArthur, R. D., et al. (2008). Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance: AIDS Vol 22(1) Jan 2008, 75-82.
 * Garland, W. H., Wohl, A. R., Valencia, R., Witt, M. D., Squires, K., Kovacs, A., et al. (2007). The acceptability of a directly-administered antiretroviral therapy (DAART) intervention among patients in public HIV clinics in Los Angeles, California: AIDS Care Vol 19(2) Feb 2007, 159-167.
 * Gauchet, A., Tarquinio, C., & Fischer, G. (2007). Psychosocial predictors of medication adherence among persons living with HIV: International Journal of Behavioral Medicine Vol 14(3) 2007, 141-150.
 * Gebrekristos, H. T., Lurie, M. N., Mthethwa, N., & Karim, Q. A. (2005). Knowledge and acceptability of HAART among TB patients in Durban, South Africa: AIDS Care Vol 17(6) Aug 2005, 767-772.
 * Gellaitry, G., Cooper, V., Davis, C., Fisher, M., Leake Date, H., & Horne, R. (2005). Patients' perception of information about HAART: Impact on treatment decisions: AIDS Care Vol 17(3) Apr 2005, 367-376.
 * George, G. (2006). Workplace ART programmes: Why do companies invest in them and are they working? : African Journal of AIDS Research Vol 5(2) 2006, 179-188.
 * Gerard, Y., Melliez, H., Mouton, Y., & Yazdanpanah, Y. (2006). Mitochondrial cytopathies associated with HIV infection: Revue Neurologique Vol 162(1) Jan 2006, 62-70.
 * Gerbert, B., Bronstone, A., Clanon, K., Abercrombie, P., & Bangsberg, D. (2000). Combination antiretroviral therapy: Health care providers confront emerging dilemmas: AIDS Care Vol 12(4) Aug 2000, 409-421.
 * Giancola, M. L., Lorenzini, P., Balestra, P., Larussa, D., Baldini, F., Corpolongo, A., et al. (2006). Neuroactive Antiretroviral Drugs Do Not Influence Neurocognitive Performance in Less Advanced HIV-lnfected Patients Responding to Highly Active Antiretroviral Therapy: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 41(3) Mar 2006, 332-337.
 * Gill, C. J., Hamer, D. H., Simon, J. L., Thea, D. M., & Sabin, L. L. (2005). No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa: AIDS Vol 19(12) Aug 2005, 1243-1249.
 * Gir, E., Vaichulonis, C. G., & de Oliveira, M. D. (2005). Adhesion to anti-retroviral therapy by individuals with HIV/AIDS attended at an institution in the interior of Sao Paulo: Revista Latino-Americana de Enfermagem Vol 13(5) Sep-Oct 2005, 634-641.
 * Glass, T. R., De Geest, S., Weber, R., Vernazza, P. L., Rickenbach, M., Furrer, H., et al. (2006). Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients: The Swiss HIV Cohort Study: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 41(3) Mar 2006, 385-392.
 * Glutzer, E., & Lalezari, J. P. (2005). Enfuvirtide for Nurses: Answering Patient Questions on Activity, Safety, and Lifestyle Impact: JANAC: Journal of the Association of Nurses in AIDS Care Vol 16(5) Sep-Oct 2005, 26-34.
 * Godin, G., Cote, J., Naccache, H., Lambert, L. D., & Trottier, S. (2005). Prediction of adherence to antiretroviral therapy: A one-year longitudinal study: AIDS Care Vol 17(4) May 2005, 493-504.
 * Godin, G., Gagne, C., & Naccache, H. (2003). Validation of a self-reported questionnaire assessing adherence to antiretroviral medication: AIDS Patient Care and STDs Vol 17(7) Jul 2003, 325-332.
 * Goicoechea, M., Best, B., Seefried, E., Wagner, G., Capparelli, E., & Haubrich, R. (2006). Failure of Modified Directly Observed Therapy Combined with Therapeutic Drug Monitoring to Enhance Antiretroviral Adherence in a Patient with Major Depression: AIDS Patient Care and STDs Vol 20(4) Apr 2006, 233-237.
 * Gold, R. S., Hinchy, J., & Batrouney, C. G. (2000). The reasoning behind decisions not to take up antiretroviral therapy in Australians infected with HIV: International Journal of STD & AIDS Vol 11(6) Jun 2000, 361-370.
 * Golin, C., Isasi, F., Bontempi, J. B., & Eng, E. (2002). Secret pills: HIV-positive patients' experiences taking antiretroviral therapy in North Carolina: AIDS Education and Prevention Vol 14(4) Aug 2002, 318-329.
 * Golin, C. E., Earp, J., Tien, H.-C., Stewart, P., Porter, C., & Howie, L. (2006). A 2-Arm, Randomized, Controlled Trial of a Motivational Interviewing-Based Intervention to Improve Adherence to Antiretroviral Therapy (ART) Among Patients Failing or Initiating ART: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 42(1) May 2006, 42-51.
 * Gonzalez, A., & Everall, I. P. (1998). Lest we forget: Neuropsychiatry and the new generation anti-HIV drugs: AIDS Vol 12(18) Dec 1998, 2365-2367.
 * Gonzalez, J. S., Penedo, F. J., Llabre, M. M., Duran, R. E., Antoni, M. H., Schneiderman, N., et al. (2007). Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence: Annals of Behavioral Medicine Vol 34(1) Aug 2007, 46-55.
 * Gordillo, V., del Amo, J., Soriano, V., & Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy: AIDS Vol 13(13) Sep 1999, 1763-1769.
 * Gordon, C. M. (2006). Commentary on Meta-Analysis of Randomized Controlled Trials for HIV Treatment Adherence Interventions: Research Directions and Implications for Practice: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S36-S40.
 * Gouvernet, B., & Viaux, J. L. (2006). Mastery and relation to antiretroviral treatments: Annales Medico-Psychologiques Vol 164(6) Aug 2006, 470-475.
 * Gray, A. (2005). The challenges of implementing antiretroviral treatment in South Africa. New York, NY: Cambridge University Press.
 * Greenblatt, D. J., von Moltke, L. L., Daily, J. P., Harmatz, J. S., & Shader, R. I. (1999). Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction: Journal of Clinical Psychopharmacology Vol 19(4) Aug 1999, 293-296.
 * Grierson, J., de Visser, R., & Bartos, M. (2001). More cautious, more optimistic: Australian people living with HIV/AIDS, 1997-1999: International Journal of STD & AIDS Vol 12(10) Oct 2001, 670-676.
 * Grodesky, M. J. (2007). The problem of non-adherence: An ethnographic study of the symbolic meanings associated with Human Immunodeficiency Virus (HIV) infection and treatment with highly active antiretroviral therapy (HAART). Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Gwadz, M., De Vogli, R., Rotheram-Borus, M. J., Diaz, M. M., Cisek, T., James, N. B., et al. (1999). Behavioral practices regarding combination therapies for HIV/AIDS: Journal of Sex Education & Therapy Vol 24(1-2) 1999, 81-88.
 * Halkitis, P. N., Parsons, J. T., Wolitski, R. J., & Remien, R. H. (2003). Characteristics of HIV antiretroviral treatments, access and adherence in an ethnically diverse sample of men who have sex with men: AIDS Care Vol 15(1) Feb 2003, 89-102.
 * Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., et al. (2006). Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel: JAMA: Journal of the American Medical Association Vol 296(7) Aug 2006, 827-843.
 * Hansen, B. A., Greenberg, K. S., & Richter, J. A. (1996). Ganciclovir-induced psychosis: New England Journal of Medicine Vol 335(18) Oct 1996, 1397.
 * Hansudewechakul, R., Jourdain, G., & Plangraun, N. (2006). A comprehensive programme to strengthen adherence to antiretroviral drug therapy and achieve virological control in HIV infected children in Thailand: Vulnerable Children and Youth Studies Vol 1(2) Aug 2006, 180-191.
 * Harding, R., Molloy, T., Easterbrook, P., Frame, K., & Higginson, I. J. (2006). Is antiretroviral therapy associated with symptom prevalence and burden: International Journal of STD & AIDS Vol 17(6) Jun 2006, 400-405.
 * Hardon, A. (2005). Confronting the HIV/AIDS epidemic in sub-Saharan Africa: Policy versus practice: International Social Science Journal Vol 57(186) Dec 2005, 601-608.
 * Hargrave, D. R., & Webb, D. W. (1998). Movement disorders in association with herpes simplex virus encephalitis in children: A review: Developmental Medicine & Child Neurology Vol 40(9) Sep 1998, 640-642.
 * Harzke, A. J., Williams, M. L., Nilsson-Schonnesson, L., Ross, M. W., Timpson, S., & Keel, K. B. (2004). Psychosocial factors associated with adherence to antiretroviral medications in a sample of HIV-positive African American drug users: AIDS Care Vol 16(4) Apr 2004, 458-470.
 * Haug, N. N., Sorenson, J. L., Gruber, V. A., Lollo, N., & Roth, G. (2006). HAART Adherence Strategies for Methadone Clients Who Are HIV-Positive: A Treatment Manual for Implementing Contingency Management and Medication Coaching: Behavior Modification Vol 30(6) Nov 2006, 752-781.
 * Hayman-Abello, S. E. (2007). The effects of highly active antiretroviral therapy (HAART) on neuropsychological status in HIV-infection: A prospective study. Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Heald, S. (2006). Abstain or Die: The Development of HIV/AIDS Policy in Botswana: Journal of Biosocial Science Vol 38(1) Jan 2006, 29-41.
 * Heckman, J. (2008). Adherence impedances to HIV/AIDS medications among a rural six-county northeastern Pennsylvania HIV/AIDS-infected population. Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Heitman, E., & Ross, M. W. (1999). Ethical issues in the use of new treatments for HIV. Dordrecht, Netherlands: Kluwer Academic Publishers.
 * Hellden, A., Odar-Cederlof, I., Larsson, K., Fehrman-Ekholm, I., & Linden, T. (2007). Death delusion: BMJ: British Medical Journal Vol 335(7633) Dec 2007, 1305.
 * Hernandez, S. O., Martin, L. L., Carrobles, J. A., & Aznar, C. M. (2006). Adherence to antiretroviral therapy and anxiety, depression, and stress in subjects within a methadone maintenance program: Ansiedad y Estres Vol 12(1) 2006, 19-30.
 * Herning, R. I., Tate, K., Better, W., & Cadet, J. L. (2002). Cerebral blood flow pulsatility deficits in HIV+ poly substance abusers: Differences associated with antiviral medications: Drug and Alcohol Dependence Vol 65(2) Jan 2002, 129-135.
 * Hess, C., Altfeld, M., Thomas, S. Y., Addo, M. M., Rosenberg, E. S., Allen, T. M., et al. (2004). HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication: Lancet Vol 363(9412) Mar 2004, 863-866.
 * Higgins, N., Zingman, B. S., Slish, J., Reichman, R. C., Fischl, M. A., Gripshover, B., et al. (2007). Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir: The American Journal on Addictions Vol 16(6) Nov 2007, 488-494.
 * Hill, Z., Kendall, C., & Fernandez, M. (2003). Patterns of Adherence to Antiretrovirals: Why Adherence Has No Simple Measure: AIDS Patient Care and STDs Vol 17(10) Oct 2003, 519-525.
 * Himelhoch, S., Powe, N. R., Breakey, W., & Gebo, K. A. (2007). Schizophrenia, AIDS and the Decision to Prescribe HAART: Results of a National Survey of HIV Clinicians: Journal of Prevention & Intervention in the Community Vol 33(1-2) 2007, 109-120.
 * Holmes, W. C., Bilker, W. B., Wang, H., Chapman, J., & Gross, R. (2007). HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(3) Nov 2007, 323-327.
 * Holmes, W. C., Pace, J. L., & Frank, I. (2007). Appropriateness of antiretroviral therapy in clients of an HIV/AIDS case management organization: AIDS Care Vol 19(2) Feb 2007, 273-281.
 * Holstad, M. K. M., Pace, J. C., De, A. K., & Ura, D. R. (2006). Factors Associated With Adherence to Antiretroviral Therapy: JANAC: Journal of the Association of Nurses in AIDS Care Vol 17(2) Mar-Apr 2006, 4-15.
 * Horberg, M. A., Silverberg, M. J., Hurley, L. B., Towner, W. J., Klein, D. B., Bersoff-Matcha, S., et al. (2008). Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(3) Mar 2008, 384-390.
 * Horne, R., Cooper, V., & Fisher, M. (2008). Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: Understanding physician and patient perspectives: AIDS Care Vol 20(9) Oct 2008, 1029-1038.
 * Hounton, S. H., Akonde, A., Zannou, D. M., Bashi, J., Meda, N., & Newlands, D. (2008). Costing universal access of highly active antiretroviral therapy in Benin: AIDS Care Vol 20(5) May 2008, 582-587.
 * Howard, A. A., Arnsten, J. H., Lo, Y., Vlahov, D., Rich, J. D., Schuman, P., et al. (2002). A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women: AIDS Vol 16(16) Nov 2002, 2175-2182.
 * Huang, L., Quartin, A., Jones, D., & Havlir, D. V. (2006). Intensive Care of Patients with HIV Infection: New England Journal of Medicine Vol 355(2) Jul 2006, 173-181.
 * Hubbard, M. (2006). Dealing With the Obstacles in Adhering to Highly Active Antiretroviral Therapy: JANAC: Journal of the Association of Nurses in AIDS Care Vol 17(1) Jan-Feb 2006, 18-25.
 * Hubben, G. A. A., Bishai, D., Pechlivanoglou, P., Cattelan, A. M., Grisetti, R., Facchin, C., et al. (2008). The societal burden of HIV/AIDS in Northern Italy: An analysis of costs and quality of life: AIDS Care Vol 20(4) Apr 2008, 449-455.
 * Hult, B., Chana, G., Masliah, E., & Everall, I. (2008). Neurobiology of HIV: International Review of Psychiatry Vol 20(1) Feb 2008, 3-13.
 * Ironson, G., O'Cleirigh, C., Fletcher, M. A., Laurenceau, J. P., Balbin, E., Klimas, N., et al. (2005). Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment: Psychosomatic Medicine Vol 67(6) Nov-Dec 2005, 1013-1021.
 * Jaggy, C., von Overbeck, J., Ledergerber, B., Schwarz, C., Egger, M., Rickenbach, M., et al. (2003). Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population: Lancet Vol 362(9387) Sep 2003, 877-878.
 * Jani, A. A. (2006). Metabolic Complications of Highly Active Antiretroviral Therapy (HAART): Beal, Jeffrey (Ed); Orrick, Joanne J (Ed); Alfonso, Kimberly (Ed).
 * Jani, A. A., Stewart, A., Nolen, R. D., & Tavel, L. (2006). Medication Adherence and Patient Education: Beal, Jeffrey (Ed); Orrick, Joanne J (Ed); Alfonso, Kimberly (Ed).
 * Jelsma, J., MacLean, E., Hughes, J., Tinise, X., & Darder, M. (2005). An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART: AIDS Care Vol 17(5) Jul 2005, 579-588.
 * Johnson, M. A., Gathe, J. C., Jr., Podzamczer, D., Molina, J.-M., Naylor, C. T., Chiu, Y.-L., et al. (2006). A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared with a Twice-Daily Regimen: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(2) Oct 2006, 153-160.
 * Johnson, M. O., Chesney, M. A., Goldstein, R. B., Remien, R. H., Catz, S., Gore-Felton, C., et al. (2006). Positive Provider Interactions, Adherence Self-Efficacy, and Adherence to Antiretroviral Medications Among HIV-Infected Adults: A Mediation Model: AIDS Patient Care and STDs Vol 20(4) Apr 2006, 258-268.
 * Johnson, M. O., Elliott, T. R., Neilands, T. B., Morin, S. F., & Chesney, M. A. (2006). A social problem-solving model of adherence to HIV medications: Health Psychology Vol 25(3) May 2006, 355-363.
 * Johnson, M. O., Stallworth, T., & Neilands, T. B. (2003). The Drugs or the Disease? Causal Attributions of Symptoms Held by HIV-Positive Adults on HAART: AIDS and Behavior Vol 7(2) Jun 2003, 109-117.
 * Jourdain, G., Ngo-Giang-Huong, N., Coeur, S. L., Bowonwatanuwong, C., Kantipong, P., Leechanachai, P., et al. (2004). Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy: New England Journal of Medicine Vol 351(3) Jul 2004, 229-240.
 * Kagaayi, J., Dreyfuss, M. L., Kigozi, G., Chen, M. Z., Wabwire-Mangen, F., Serwadda, D., et al. (2005). Maternal Self-Medication and Provision of Nevirapine to Newborns by Women in Rakai, Uganda: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 39(1) May 2005, 121-124.
 * Kagaayi, J., Makumbi, F., Nakigozi, G., Wawer, M. J., Gray, R. H., Serwadda, D., et al. (2007). WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai District, Uganda: AIDS Vol 21(9) May 2007, 1208-1210.
 * Kaharuza, F. M., Bunnell, R., Moss, S., Purcell, D. W., Bikaako-Kajura, W., Wamai, N., et al. (2006). Depression and CD4 cell count among persons with HIV infection in Uganda: AIDS and Behavior Vol 10(Suppl1) July 2006, S105-S111.
 * Kalayjian, R. C., Franceschini, N., Gupta, S. K., Szczech, L. A., Mupere, E., Bosch, R. J., et al. (2008). Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease: AIDS Vol 22(4) Feb 2008, 481-487.
 * Kalichman, S. C. (1998). Post-exposure prophylaxis for HIV infection in gay and bisexual men: American Journal of Preventive Medicine Vol 15(2) Aug 1998, 120-127.
 * Kalichman, S. C., Cain, D., Cherry, C., Kalichman, M., & Pope, H. (2005). Pillboxes and Antiretroviral Adherence: Prevalence of Use, Perceived Benefits, and Implications for Electronic Medication Monitoring Devices: AIDS Patient Care and STDs Vol 19(12) Dec 2005, 833-839.
 * Kalichman, S. C., & Ramachandran, B. (1999). Mental health implications of new HIV treatments. Dordrecht, Netherlands: Kluwer Academic Publishers.
 * Kamiru, H. N. (2007). Evaluation of a training program to increase the capacity of health care providers to provide antiretroviral therapy to pediatric patients in sub-Saharan Africa. Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Kapadia, F., Cook, J. A., Cohen, M. H., Sohler, N., Kovacs, A., Greenblatt, R. M., et al. (2005). The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use: Addiction Vol 100(7) Jul 2005, 990-1002.
 * Kapadia, F., Vlahov, D., Wu, Y., Cohen, M. H., Greenblatt, R. M., Howard, A. A., et al. (2008). Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women: American Journal of Drug and Alcohol Abuse Vol 34(2) 2008, 161-170.
 * Kaplan, C. P., & Bain, K. P. (1999). Cognitive outcome after emergent treatment of acute herpes simplex encephalitis with acyclovir: Brain Injury Vol 13(11) Nov 1999, 935-941.
 * Kassaye, S. G., Ndayishimiye, F., Binswanger, H., Sall, A. Y., Machekano, R., & Israelski, D. M. (2006). Association-driven care and treatment: A model for community-based delivery of HIV/AIDS healthcare in resource-limited settings: AIDS Vol 20(11) Jul 2006, 1561-1562.
 * Kastrissios, H., Suarez, J.-R., Katzenstein, D., Girard, P., Sheiner, L. B., & Blaschke, T. F. (1998). Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial: AIDS Vol 12(17) Dec 1998, 2295-2303.
 * Katlama, C. (1996). Consequences for the management of cytomegalovirus: AIDS Vol 10(Suppl 1) Nov 1996, S43-S46.
 * Katlama, C., Mouthon, B., Gourdon, D., & Lapierre, D. (1996). Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance: AIDS Vol 10(10) Sep 1996, 1107-1112.
 * Katz, M. H. (1994). Effect of HIV treatment on cognition, behavior, and emotion: Psychiatric Clinics of North America Vol 17(1) Mar 1994, 227-230.
 * Kedmi, M., Maayan, S., Cohen, S. B., Hauzi, M., & Rund, D. (2007). MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease: AIDS Patient Care and STDs Vol 21(9) Sep 2007, 653-658.
 * Kelly, J. A., Otto-Salaj, L. L., Sikkema, K. J., Pinkerton, S. D., & Bloom, F. R. (1998). Implications of HIV treatment advances for behavioral research on AIDS: Protease inhibitors and new challenges in HIV secondary prevention: Health Psychology Vol 17(4) Jul 1998, 310-319.
 * Kemppainen, J. K., Levine, R. E., Mistal, M., & Schmidgall, D. (2001). HAART adherence in culturally diverse patients with HIV/AIDS: A study of male patients from a Veteran's Administration hospital in Northern California: AIDS Patient Care and STDs Vol 15(3) Mar 2001, 117-127.
 * Kennedy, C., O'Reilly, K., Medley, A., & Sweat, M. (2007). The impact of HIV treatment on risk behaviour in developing countries: A systematic review: AIDS Care Vol 19(6) Jul 2007, 707-720.
 * Kennedy, S. B. I. V. (2000). Developing a self-administered tool to predict adherence to antiretroviral therapy: Design, method, and objectives: AIDS Patient Care and STDs Vol 14(6) Jun 2000, 309-316.
 * Kiguba, R., Byakika-Tusiime, J., Karamagi, C., Ssali, F., Mugyenyi, P., & Katabira, E. (2007). Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: Prevalence and associated factors: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 45(2) Jun 2007, 218-223.
 * Kim, T. W., Palepu, A., Cheng, D. M., Libman, H., Saitz, R., & Samet, J. H. (2007). Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems: AIDS Care Vol 19(8) Sep 2007, 1039-1047.
 * Kimmerling, M., Wagner, G., & Ghosh-Dastidar, B. (2003). Factors associated with accurate self-reported adherence to HIV antiretrovirals: International Journal of STD & AIDS Vol 14(4) Apr 2003, 281-284.
 * Kitahata, M. M., Reed, S. D., Dillingham, P. W., Van Rompaey, S. E., Young, A. A., Harrington, R. D., et al. (2004). Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death: International Journal of STD & AIDS Vol 15(12) Dec 2004, 803-810.
 * Kitajima, T., Kobayashi, Y., Chaipah, W., Sato, H., Toyokawa, S., Chadbunchachai, W., et al. (2005). Access to antiretroviral therapy among HIV/AIDS patients in Khon Kaen Province, Thailand: AIDS Care Vol 17(3) Apr 2005, 359-366.
 * Knowlton, A. R., Arnsten, J. H., Gourevitch, M. N., Eldred, L., Wilkinson, J. D., Rose, C. D., et al. (2007). Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: The role of informal caregiving and household factors: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(Suppl 2) Nov 2007, S110-S119.
 * Koenig, L. J., & Bachanas, P. J. (2006). Adherence to Medications for HIV: Teens Say, "Too Many, Too Big, Too Often". Westport, CT: Praeger Publishers/Greenwood Publishing Group.
 * Kombe, G., Fieno, J., Bhatt, P., & Smith, J. (2005). Highly active anti-retroviral treatment as a bridge towards education for all in sub-Saharan Africa: International Social Science Journal Vol 57(186) Dec 2005, 609-620.
 * Kovacs, A., & Connors, M. (2004). HIV-1 and immune control: can we change the course of HIV-1? : Lancet Vol 363(9412) Mar 2004, 833-834.
 * Koziel, M. J., & Peters, M. G. (2007). Viral hepatitis in HIV infection: New England Journal of Medicine Vol 356(14) Apr 2007, 1445-1454.
 * Krebs, D. W., Chi, B. H., Mulenga, Y., Morris, M., Cantrell, R. A., Mulenga, L., et al. (2008). Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia: AIDS Care Vol 20(3) Mar 2008, 311-317.
 * Krentz, H. B., & Gill, M. J. (2005). Impact of Practice Changes on an Antiretroviral Budget in an HIV Care Program: Disease Management & Health Outcomes Vol 13(3) 2005, 209-217.
 * Kuhn, L., Thea, D. M., & Aldrovandi, G. M. (2007). Bystander effects: Children who escape infection but not harm: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(5) Dec 2007, 517-518.
 * Kumar, A., Kilaru, K. R., Sippy, N., Carter, A. O., & Roach, T. C. (2005). Efficacy of Highly Active Antiretroviral Therapy in Nonclinical Trial Setting of a Developing Caribbean Country: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 40(1) Sep 2005, 114-116.
 * Kumarasamy, N., Safren, S. A., Raminani, S. R., Pickard, R., James, R., Sri Krishnan, A. K., et al. (2005). Barriers and Facilitators to Antiretroviral Medication Adherence Among Patients with HIV in Chennai, India: A Qualitative Study: AIDS Patient Care and STDs Vol 19(8) Aug 2005, 526-537.
 * Kuo, W.-H., Wilson, T. E., Weber, K. M., Madhava, V., Richardson, J., Delapenha, R., et al. (2004). Initiation of Regular Marijuana Use Among a Cohort of Women Infected with or at Risk for HIV in the Women's Interagency HIV Study (WIHS): AIDS Patient Care and STDs Vol 18(12) Dec 2004, 702-713.
 * lacobellis, G., Pellicelli, A. M., Grisorio, B., Barbarini, G., Leonetti, F., Sharma, A. M., et al. (2008). Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat: Obesity Vol 16(1) Jan 2008, 179-183.
 * Laine, C., Hauck, W. W., & Turner, B. J. (2002). Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users: Medical Care Vol 40(10) Oct 2002, 976-995.
 * Lallemant, M., Jourdain, G., Coeur, S. L., Mary, J. Y., Ngo-Giang-Huong, N., Koetsawang, S., et al. (2004). Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in Thailand: New England Journal of Medicine Vol 351(3) Jul 2004, 217-228.
 * Landman, R., Moatti, J.-P., Perrin, V., Huard, P., & Group, P. S. (2000). Variability of attitudes toward early initiation of HAART for HIV infection: A study of French prescribing physicians: AIDS Care Vol 12(6) Dec 2000, 711-716.
 * Larson, B. A., Fox, M. P., Rosen, S., Bii, M., Sigei, C., Shaffer, D., et al. (2008). Early effects of antiretroviral therapy on work performance: Preliminary results from a cohort study of Kenyan agricultural workers: AIDS Vol 22(3) Jan 2008, 421-425.
 * Law, M. G., Prestage, G., Grulich, A., Van de Ven, P., & Kippax, S. (2001). Modelling the effect of combination antiretroviral treatments on HIV incidence: AIDS Vol 15(10) Jul 2001, 1287-1294.
 * Lawrence, J., Hullsiek, K. H., Thackeray, L. M., Abrams, D. I., Crane, L. R., Mayers, D. L., et al. (2006). Disadvantages of Structured Treatment Interruption Persist in Patients with Multidrug-Resistant HIV-1: Final Results of the CPCRA 064 Study: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(2) Oct 2006, 169-178.
 * Leclerc-Madlala, S. (2006). 'We will eat when I get the grant': Negotiating AIDS, poverty and antiretroviral treatment in South Africa: African Journal of AIDS Research Vol 5(3) 2006, 249-256.
 * Lee, S. S., Ma, K., Chu, E. K. Y., & Wong, K. H. (2007). The phenomenon of missing doses in a cohort of HIV patients with good adherence to highly active antiretroviral therapy: International Journal of STD & AIDS Vol 18(3) Mar 2007, 167-170.
 * Lekas, H.-M., Siegel, K., & Schrimshaw, E. W. (2006). Continuities and Discontinuities in the Experiences of Felt and Enacted Stigma Among Women With HIV/AIDS: Qualitative Health Research Vol 16(9) Nov 2006, 1165-1190.
 * Lem, M., Moore, D., Marion, S., Bonner, S., Chan, K., O'Connell, J., et al. (2005). Back to work: Correlates of employment among persons receiving highly active antiretroviral therapy: AIDS Care Vol 17(6) Aug 2005, 740-746.
 * Leroy, V., Sakarovitch, C., Cortina-Borja, M., McLntyre, J., Coovadia, H., Dabis, F., et al. (2005). Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? : AIDS Vol 19(16) Nov 2005, 1865-1875.
 * Lester, R. T., Gelmon, L., & Plummer, F. A. (2006). Cell phones: Tightening the communication gap in resource-limited antiretroviral programmes? : AIDS Vol 20(17) Nov 2006, 2242-2244.
 * Letendre, S., Marquie-Beck, J., Capparelli, E., Best, B., Clifford, D., Collier, A. C., et al. (2008). Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system: Archives of Neurology Vol 65(1) Jan 2008, 65-70.
 * Levine, A. J., Hinkin, C. H., Castellon, S. A., Mason, K. I., Lam, M. N., Perkins, A., et al. (2005). Variations in patterns of highly active antiretroviral therapy (HAART) adherence: AIDS and Behavior Vol 9(3) Sep 2005, 355-362.
 * Levine, A. J., Hinkin, C. H., Marion, S., Keuning, A., Castellon, S. A., Lam, M. M., et al. (2006). Adherence to antiretroviral medications in HIV: Differences in data collected via self-report and electronic monitoring: Health Psychology Vol 25(3) May 2006, 329-335.
 * Lewden, C., Chene, G., Morlat, P., Raffi, F., Dupon, M., Dellamonica, P., et al. (2007). HIV-infected adults with a CD4 cell count greater than 500 cells/mmsuperscript 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(1) Sep 2007, 72-77.
 * Lewin, S. R., Murray, J. M., Solomon, A., Wightman, F., Cameron, P. U., Purcell, D. J., et al. (2008). Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(2) Feb 2008, 140-147.
 * Lewis, M. P., Colbert, A., Erlen, J., & Meyers, M. (2006). A qualitative study of persons who are 100% adherent to antiretroviral therapy: AIDS Care Vol 18(2) Feb 2006, 140-148.
 * Lichtenstein, K. A., Armon, C., Buchacz, K., Chmiel, J. S., Moorman, A. C., Wood, K. C., et al. (2008). Initiation of antiretroviral therapy at CD4 cell counts >=350 cells/mmsuperscript 3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(1) Jan 2008, 27-35.
 * Lima, V. D., Geller, J., Bangsberg, D. R., Patterson, T. L., Daniel, M., Kerr, T., et al. (2007). The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART: AIDS Vol 21(9) May 2007, 1175-1183.
 * Limb, S., Kawsar, M., & Forster, G. E. (2002). HIV post-exposure prophylaxis after sexual assault: The experience of a sexual assault service in London: International Journal of STD & AIDS Vol 13(9) Sep 2002, 602-605.
 * Liu, C., Ostrow, D., Detels, R., Hu, Z., Johnson, L., Kingsley, L., et al. (2006). Impacts of HIV infection and HAART use on quality of life: Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation Vol 15(6) Aug 2006, 941-949.
 * Liu, H., Miller, L. G., Hays, R. D., Wagner, G., Colin, C. E., Hu, W., et al. (2006). A Practical Method to Calibrate Self-Reported Adherence to Antiretroviral Therapy: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S104-S112.
 * Liu, H., Miller, L. G., Hays, R. D., Wagner, G., Colin, C. E., Hu, W., et al. (2007). "A practical method to calibrate self-reported adherence to antiretroviral therapy": Erratum: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 45(1) May 2007, 129.
 * Llabre, M. M., Weaver, K. E., Duran, R. E., Antoni, M. H., McPherson-Baker, S., & Schneiderman, N. (2006). A Measurement Model of Medication Adherence to Highly Active Antiretroviral Therapy and its Relation to Viral Load in HIV-Positive Adults: AIDS Patient Care and STDs Vol 20(10) Oct 2006, 701-711.
 * Locher, A. W., Pargament, K., & Duggan, J. (2007). Antiretroviral therapy in the lives of women of colour with HIV: AIDS Care Vol 19(8) Sep 2007, 1048-1051.
 * Loftis, J. M., Hauser, P., & Rifai, M. A. (2005). The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin: Brain, Behavior, and Immunity Vol 19(4) Jul 2005, 271-272.
 * Lortholary, O., Poizat, G., Zeller, V., Neuville, S., Boibieux, A., Alvarez, M., et al. (2006). Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy: AIDS Vol 20(17) Nov 2006, 2183-2191.
 * Loughlin, A. M., Metsch, L., Gardner, L., Anderson-Mahoney, P., Barrigan, M., & Strathdee, S. (2004). Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users: AIDS Care Vol 16(4) Apr 2004, 485-500.
 * Low-Beer, S., Chan, K., Wood, E., Yip, B., Montaner, J. S. G., O'Shaughnessy, M. V. O., et al. (2000). Health related quality of life among persons with HIV after the use of protease inhibitors: Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation Vol 9(8) 2000, 941-949.
 * Lowrance, D., Makombe, S., Harries, A., Yu, J., Aberle-Grasse, J., Eiger, O., et al. (2007). Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(1) Sep 2007, 56-61.
 * Lowy, A., Page, J., Jaccard, R., Ledergerber, B., Somaini, B., Weber, R., et al. (2005). Costs of treatment of Swiss patients with HIV on antiretroviral therapy in hospital-based and general practice-based care: A prospective cohort study: AIDS Care Vol 17(6) Aug 2005, 698-710.
 * Lucas, G. M., Gebo, K. A., Chaisson, R. E., & Moore, R. D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic: AIDS Vol 16(5) Mar 2002, 767-774.
 * Lucas, G. M., Mullen, B. A., McCaul, M. E., Weidle, P. J., Hader, S., & Moore, R. D. (2007). Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy: AIDS Patient Care and STDs Vol 21(8) Aug 2007, 564-574.
 * Luszczynska, A., Sarkar, Y., & Knoll, N. (2007). Received social support, self-efficacy, and finding benefits in disease as predictors of physical functioning and adherence to antiretroviral therapy: Patient Education and Counseling Vol 66(1) Apr 2007, 37-42.
 * Ma, K., Lee, S.-S., Chu, E. K. Y., Tam, D. K. P., Kwong, V. S. C., Ho, C.-F., et al. (2008). Popular use of traditional Chinese medicine in HIV patients in the HAART era: AIDS and Behavior Vol 12(4) Jul 2008, 637-642.
 * Maenza, J. R., & Chaisson, R. E. (1996). HIV disease and its treatment: Current status and future prospects: International Review of Psychiatry Vol 8(2-3) Sep 1996, 167-175.
 * Maggi, J. D., & Halman, M. H. (2001). The effect of divalproex sodium on viral load: A retrospective review of HIV-positive patients with manic syndromes: The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie Vol 46(4) May 2001, 359-362.
 * Maisels, L., Steinberg, J., & Tobias, C. (2001). An investigation of why eligible patients do not receive HAART: AIDS Patient Care and STDs Vol 15(4) Apr 2001, 185-191.
 * Malan, D. R., Krantz, E., David, N., Wirtz, V., Hammond, J., & McGrath, D. (2008). Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(2) Feb 2008, 161-167.
 * Malonza, I. M., Richardson, B. A., Kreiss, J. K., Bwayo, J. J., & Stewart, G. C. J. (2003). The effect of rapid HIV-1 testing on uptake of perinatal HIV-1 interventions: a randomized clinical trial: AIDS Vol 17(1) Jan 2003, 113-118.
 * Malow, R. M., Baker, S. M., Klimas, N., Antoni, M. H., Schneiderman, N., Penedo, F. J., et al. (1998). "Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers": Erratum: Psychiatric Services Vol 49(11) Nov 1998, 1487.
 * Malow, R. M., McPherson, S., Klimas, N., Antoni, M. H., Schneiderman, N., Penedo, F. J., et al. (1998). Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers: Psychiatric Services Vol 49(8) Aug 1998, 1021-1022.
 * Malta, M., Strathdee, S. A., Magnanini, M. M. F., & Bastos, F. I. (2008). Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review: Addiction Vol 103(8) Aug 2008, 1242-1257.
 * Maneesriwongul, W. L., Tulathong, S., Fennie, K. P., & Williams, A. B. (2006). Adherence to Antiretroviral Medication Among HIV-Positive Patients in Thailand: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S119-S122.
 * Mannheimer, S., Thackeray, L., Hullsiek, K. H., Chesney, M., Gardner, E. M., Wu, A. W., et al. (2008). A randomized comparison of two instruments for measuring self-reported antiretroviral adherence: AIDS Care Vol 20(2) Feb 2008, 161-169.
 * Mannheimer, S. B., Morse, E., Matts, J. P., Andrews, L., Child, C., Schmetter, B., et al. (2006). Sustained Benefit from a Long-Term Antiretroviral Adherence Intervention: Results of a Large Randomized Clinical Trial: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S41-S47.
 * Manosuthi, W., Sungkanuparph, S., Ruxrungtham, K., Prasithsirikul, W., Athichathanabadi, C., Tantisiriwat, W., et al. (2008). Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(1) Jan 2008, 127-129.
 * Mansoor, L., & Dowse, R. (2007). Written medicines information for South African HIV/AIDS patients: Does it enhance understanding of co-trimoxazole therapy? : Health Education Research Vol 22(1) Feb 2007, 37-48.
 * Manzardo, C., Zaccarelli, M., Aguero, F., Antinori, A., & Miro, J. M. (2007). Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(Suppl1) Sep 2007, S9-S18.
 * Marcellin, F., Carrieri, M. P., Peretti-Watel, P., Bouhnik, A.-D., Obadia, Y., Lert, F., et al. (2006). Do Migrants Overreport Adherence to Highly Active Antiretroviral Therapies?: Results From the French VESPA (ANRS-EN12) National Survey: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 42(5) Aug 2006, 646-647.
 * Marhefka, S. L., Tepper, V. J., Brown, J. L., & Farley, J. J. (2006). Caregiver Psychosocial Characteristics and Children's Adherence to Antiretroviral Therapy: AIDS Patient Care and STDs Vol 20(6) Jun 2006, 429-437.
 * Marhefka, S. L., Tepper, V. J., Farley, J. J., Sleasman, J. W., & Mellins, C. A. (2006). Brief Report: Assessing Adherence to Pediatric Antiretroviral Regimens Using the 24-Hour Recall Interview: Journal of Pediatric Psychology Vol 31(9) Oct 2006, 989-994.
 * Mari-Dell'Olmo, M., Rodriguez-Sanz, M., Garcia-Olalla, P., Pasarin, M. I., Brugal, M. T., Cayla, J. A., et al. (2007). Individual and community-level effects in the socioeconomic inequalities of AIDS-related mortality in an urban area of southern Europe: Journal of Epidemiology & Community Health Vol 61(3) Mar 2007, 232-240.
 * Martin, B. K., Wu, A. W., Gelman, R., & Mitsuyasu, R. T. (2005). Quality of Life in a Clinical Trial of Highly Active Antiretroviral Therapy Alone or With Intravenous or Subcutaneous Interleukin-2 Administration: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 40(4) Dec 2005, 428-433.
 * Martin, C., Solders, G., Sonnerborg, A., & Hansson, P. (2000). Antiretroviral therapy may improve sensory function in HIV-infected patients: A pilot study: Neurology Vol 54(11) Jun 2000, 2120-2127.
 * Martin, E. M., Pitrak, D. L., Novak, R. M., Pursell, K. J., & Mullane, K. M. (1999). Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report: Journal of Clinical and Experimental Neuropsychology Vol 21(5) Oct 1999, 730-735.
 * Martin, F., Navaratne, L., Khan, W., Sarner, L., Mercey, D., Anderson, J., et al. (2006). Pregnant Women with HIV Infection can Expect Healthy Survival: Three-Year Follow-Up: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(2) Oct 2006, 186-192.
 * Martin, L. L., Hernandez, S. O., & Carrobles, J. A. (2005). Psychosocial variables in the antiretroviral treatment adherence in methadone maintenance patients: Psicothema Vol 17(4) Nov 2005, 575-581.
 * Martin, S., Wolters, P. L., Calabrese, S. K., Toledo-Tamula, M. A., Wood, L. V., Roby, G., et al. (2007). The antiretroviral regimen complexity index: A novel method of quantifying regimen complexity: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 45(5) Aug 2007, 535-544.
 * Martin, S. C., Wolters, P. L., Toledo-Tamula, M. A., Zeichner, S. L., Hazra, R., & Civitello, L. (2006). Cognitive Functioning in School-Aged Children With Vertically Acquired HIV Infection Being Treated With Highly Active Antiretroviral Therapy (HAART): Developmental Neuropsychology Vol 30(2) 2006, 633-657.
 * Martinez, J., Bell, D., Camacho, R., Henry-Reid, L. M., Bell, M., Watson, C., et al. (2000). Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic: Journal of the National Medical Association Vol 92(2) Feb 2000, 55-61.
 * Martinez, P., Andia, I., Emenyonu, N., Hahn, J. A., Hauff, E., Pepper, L., et al. (2008). Alcohol use, depressive symptoms and the receipt of antiretroviral therapy in Southwest Uganda: AIDS and Behavior Vol 12(4) Jul 2008, 605-612.
 * Maru, D. S.-R., Bruce, R. D., Walton, M., Mezger, J. A., Springer, S. A., Shield, D., et al. (2008). Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy: AIDS and Behavior Vol 12(2) Mar 2008, 284-293.
 * Mason, S., Watts, A., Sheils, S., & Koorey, D. (2007). Improving access to HCV treatment: External jugular venepuncture can overcome problems with difficult venous access: International Journal of Drug Policy Vol 18(5) Oct 2007, 433-436.
 * Mata, R. C., Viciana, P., De Alarcon, A., Lopez-Cortes, L. F., Gomez-Vera, J., Trastoy, M., et al. (2005). Discontinuation of Antiretroviral Therapy in Patients with Chronic HIV Infection: Clinical, Virologic, and Immunologic Consequences: AIDS Patient Care and STDs Vol 19(9) Sep 2005, 550-562.
 * Mathews, W. C., Mar-Tang, M., Ballard, C., Colwell, B., Abulhosn, K., Noonan, C., et al. (2002). Prevalence, predictors, and outcomes of early adherence after starting or changing antiretroviral therapy: AIDS Patient Care and STDs Vol 16(4) Apr 2002, 157-172.
 * Mathis, S., Gil, R., & Neau, J. P. (2006). Neurological complications of Herpes zoster: Revue Neurologique Vol 162(8-9) Sep 2006, 879-887.
 * Maticka-Tyndale, E., Adam, B. D., & Cohen, J. (2002). Sexual desire and practice among people living with HIV and using combination anti-retroviral therapies: Canadian Journal of Human Sexuality Vol 11(1) Spr 2002, 33-40.
 * Matthews, A. M., Fireman, M., Zucker, B., Sobel, M., & Hauser, P. (2006). Relapse to Opioid Use After Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin: American Journal of Psychiatry Vol 163(8) Aug 2006, 1342-1347.
 * May, M. (2007). Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies: AIDS Vol 21(9) May 2007, 1185-1197.
 * Mayer, K. H. (1999). Combination antiretroviral chemotherapy: Shifting paradigms and evolving praxis. Dordrecht, Netherlands: Kluwer Academic Publishers.
 * McCance-Katz, E., Gourevitch, M. N., Arnsten, J., Sarlo, J., Rainey, P., & Jatlow, P. (2002). Modified Directly Observed Therapy (MDOT) for injection drug users with HIV disease: The American Journal on Addictions Vol 11(4) Fal 2002, 271-278.
 * McCance-Katz, E. F., Farber, S., Selwyn, P. A., & O'Connor, A. (2000). Decrease in methadone levels with nelfinavir mesylate: American Journal of Psychiatry Vol 157(3) Mar 2000, 481.
 * McCutchan, J. A., Wu, J. W., Robertson, K., Koletar, S. L., Ellis, R. J., Cohn, S., et al. (2007). HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients: AIDS Vol 21(9) May 2007, 1109-1117.
 * McKay, A. (2003). Sex Research Update: Canadian Journal of Human Sexuality Vol 12(2) Sum 2003, 121-124.
 * McNabb, J. J., Nicolau, D. P., Stoner, J. A., & Ross, J. (2003). Patterns of adherence to antiretroviral medications: The value of electronic monitoring: AIDS Vol 17(12) Aug 2003, 1763-1767.
 * Mehling, M., Drechsler, H., Kuhle, J., Hardmeier, M., Doerries, R., Ruegg, S., et al. (2008). Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement: Journal of Neurovirology Vol 14(1) Feb 2008, 78-84.
 * Mela, C. M., Steel, A., Lindsay, J., Gazzard, B. G., Gotch, F. M., & Goodier, M. R. (2007). Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals: Journal of Neurology, Neurosurgery & Psychiatry Vol 78(11) Nov 2007, 2177-2182.
 * Melnick, S. M., Weedon, J., & Dow-Edwards, D. L. (2002). The effects of perinatal AZT exposure on the acoustic startle response in adult rats: Neurotoxicology and Teratology Vol 24(6) Nov-Dec 2002, 773-781.
 * Menon, A., Glazebrook, C., Campain, N., & Ngoma, M. (2007). Mental health and disclosure of HIV status in Zambian adolescents with HIV infection: Implications for peer-support programs: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(3) Nov 2007, 349-354.
 * Merito, M., & Pezzotti, P. (2006). Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients. Evidence from the ICONA cohort: The European Journal of Health Economics Vol 7(1) Mar 2006, 30-36.
 * Meystre-Agustoni, G., Dubois-Arber, F., Cochand, P., & Telenti, A. (2000). Antiretroviral therapies from the patient's perspective: AIDS Care Vol 12(6) Dec 2000, 717-721.
 * Milam, J., Richardson, J. L., McCutchan, A., Stoyanoff, S., Weiss, J., Kemper, C., et al. (2005). Effect of a Brief Antiretroviral Adherence Intervention Delivered by HIV Care Providers: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 40(3) Nov 2005, 356-363.
 * Miller, C. L., Spittal, P. M., Wood, E., Chan, K., Schechter, M. T., Montaner, J. S. G., et al. (2006). Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations: AIDS Care Vol 18(8) Nov 2006, 968-976.
 * Miller, L. G., & Chang, E. S. (2002). Case report: Human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy: Denial of poor medication adherence or recalcitrant infection? : AIDS Patient Care and STDs Vol 16(8) Aug 2002, 355-359.
 * Miller, L. G., Huffman, H. B., Weidmer, B. A., & Hays, R. D. (2002). Patient preferences regarding antiretroviral therapy: International Journal of STD & AIDS Vol 13(9) Sep 2002, 593-601.
 * Mills, E. J., Nachega, J. B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., et al. (2006). Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America: A Meta-Analysis: JAMA: Journal of the American Medical Association Vol 296(6) Aug 2006, 679-690.
 * Misener, T. R., & Sowell, R. L. (1998). HIV-infected women's decisions to take antiretrovirals: Western Journal of Nursing Research Vol 20(4) Aug 1998, 431-447.
 * Mitchell, C. D. (2006). HIV-1 encephalopathy among perinatally infected children: Neuropathogenesis and response to highly active antiretroviral therapy: Mental Retardation and Developmental Disabilities Research Reviews Vol 12(3) 2006, 216-222.
 * Moatti, J.-P., Prudhomme, J., Traore, D. C., Juillet-Amari, A., Akribi, H. A.-D., & Msellati, P. (2003). Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Cote d'Ivoire: AIDS Vol 17(Suppl3) Jul 2003, S69-S77.
 * Mocroft, A., Kirk, O., Gatell, J., Reiss, P., Gargalianos, P., Zilmer, K., et al. (2007). Chronic renal failure among HIV-1-infected patients: AIDS Vol 21(9) May 2007, 1119-1127.
 * Molassiotis, A., Lopez-Nahas, V., Chung, W. Y., & Lam, S. W. (2003). A pilot study of the effects of a behavioural intervention on treatment adherence in HIV-infected patients: AIDS Care Vol 15(1) Feb 2003, 125-135.
 * Molassiotis, A., Morris, K., & Trueman, I. (2007). The importance of the patient--clinician relationship in adherence to antiretroviral medication: International Journal of Nursing Practice Vol 13(6) Dec 2007, 370-376.
 * Molina, J.-M., Cohen, C., Katlama, C., Grinsztejn, B., Timerman, A., de Jesus Pedro, R., et al. (2007). Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(1) Sep 2007, 24-31.
 * Moon, S., Van Leemput, L., Durier, N., Jambert, E., Dahmane, A., Jie, Y., et al. (2008). Out-of-pocket costs of AIDS care in China: Are free antiretroviral drugs enough? : AIDS Care Vol 20(8) Sep 2008, 984-994.
 * Moore, J. S., & Rogers, M. (2002). Female-controlled prevention technologies. New York, NY: Kluwer Academic/Plenum Publishers.
 * Morasco, B. J., Rifai, M. A., Loftis, J. M., Indest, D. W., Moles, J. K., & Hauser, P. (2007). A randomized trial of paroxetine to prevent interferon-alpha -induced depression in patients with hepatitis C: Journal of Affective Disorders Vol 103(1-3) Nov 2007, 83-90.
 * Moreno, A., Barcena, R., Quereda, C., Casado, J. L., Perez-Elias, M. J., Fortun, J., et al. (2008). Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation: AIDS Vol 22(4) Feb 2008, 547-548.
 * Moreno, A., Perez-Elias, M. J., Casado, J. L., Munoz, V., Antela, A., Dronda, F., et al. (2001). Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes: AIDS Vol 15(8) May 2001, 1068-1070.
 * Morlese, J. E., Qazi, N. A., Gazzard, B. G., & Nelson, M. R. (2002). Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? : AIDS Vol 16(13) Sep 2002, 1840-1841.
 * Morrison, E. A. B., & Levenson, J. A. (2006). Medical Treatment and Occupational Exposure. Philadelphia, PA: Lippincott Williams & Wilkins Publishers.
 * Morse, D. E., Davis, H. D., Popke, E. J., Brown, K. J., O'Donoghue, V. A., & Grunberg, N. E. (1997). Effects of ddC and AZT on locomotion and acoustic startle I: Acute effects in female rats: Pharmacology, Biochemistry and Behavior Vol 56(2) Feb 1997, 221-228.
 * Msellati, P., Juillet-Amari, A., Prudhomme, J., Akribi, H. A.-D., Coulibaly-Traore, D., Souville, M., et al. (2003). Socio-economic and health characteristics of HIV-infected patients seeking care in relation to access to the Drug Access Initiative and to antiretroviral treatment in Cote d'Ivoire: AIDS Vol 17(Suppl3) Jul 2003, S63-S68.
 * Mshana, G. H., Wamoyi, J., Busza, J., Zaba, B., Changalucha, J., Kaluvya, S., et al. (2006). Barriers to Accessing Antiretroviral Therapy in Kisesa, Tanzania: A Qualitative Study of Early Rural Referrals to the National Program: AIDS Patient Care and STDs Vol 20(9) Sep 2006, 649-657.
 * Muga, R., Egea, J. M., Sanvisens, A., Arnal, J., Tural, C., Tor, J., et al. (2004). Impact of injecting drug use on the interruption of antiretroviral therapies: Journal of Epidemiology & Community Health Vol 58(4) Apr 2004, 286-287.
 * Mugavero, M., Ostermann, J., Whetten, K., Leserman, J., Swartz, M., Stangl, D., et al. (2006). Barriers to Antiretroviral Adherence: The Importance of Depression, Abuse, and Other Traumatic Events: AIDS Patient Care and STDs Vol 20(6) Jun 2006, 418-428.
 * Mukherjee, J. S., Ivers, L., Leandre, F., Farmer, P., & Behforouz, H. (2006). Antiretroviral Therapy in Resource-Poor Settings: Decreasing Barriers to Access and Promoting Adherence: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S123-S126.
 * Mukhtar-Yola, M., Adeleke, S., Gwarzo, D., & Ladan, Z. F. (2006). Preliminary investigation of adherence to antiretroviral therapy among children in Aminu Kano Teaching Hospital, Nigeria: African Journal of AIDS Research Vol 5(2) 2006, 141-144.
 * Munakata, J., Benner, J. S., Becker, S., Dezii, C. M., Hazard, E. H., & Tierce, J. C. (2006). Clinical and Economic Outcomes of Nonadherence to Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency Virus: Medical Care Vol 44(10) Oct 2006, 893-899.
 * Murphy, D. A., Lu, M. C., Martin, D., Hoffman, D., & Marelich, W. D. (2002). Results of a pilot intervention trial to improve antiretroviral adherence among HIV-positive patients: JANAC: Journal of the Association of Nurses in AIDS Care Vol 13(6) Nov-Dec 2002, 57-69.
 * Murphy, D. A., Marelich, W. D., Hoffman, D., & Steers, W. N. (2004). Predictors of antiretroviral adherence: AIDS Care Vol 16(4) Apr 2004, 471-484.
 * Murphy, D. A., Roberts, K. J., Martin, D. J., Marelich, W., & Hoffman, D. (2000). Barriers to antiretroviral adherence among HIV-infected adults: AIDS Patient Care and STDs Vol 14(1) Jan 2000, 47-58.
 * Murphy, G., Charlett, A., Jordan, L. F., Osner, N., Gill, O. N., & Parry, J. V. (2004). HIV incidence appears constant in men who have sex with men despite widespread use of effective antiretroviral therapy: AIDS Vol 18(2) Jan 2004, 265-272.
 * Mutimura, E., Stewart, A., Crowther, N. J., Yarasheski, K. E., & Cade, W. T. (2008). The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution: Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation Vol 17(3) Apr 2008, 377-385.
 * Nachega, J. B., Lehman, D. A., Hlatshwayo, D., Mothopeng, R., Chaisson, R. E., & Karstaedt, A. S. (2005). HIV/AIDS and Antiretroviral Treatment Knowledge, Attitudes, Beliefs, and Practices in HIV-Infected Adults in Soweto, South Africa: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 38(2) Feb 2005, 196-201.
 * Nadler, J. P. (2006). Antiretroviral Resistance Testing and Therapeutic Drug Monitoring: Beal, Jeffrey (Ed); Orrick, Joanne J (Ed); Alfonso, Kimberly (Ed).
 * Nattrass, N. (2006). South Africa's "Rollout" of Highly Active Antiretroviral Therapy: A Critical Assessment: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(5) Dec 2006, 618-623.
 * Nattrass, N. (2007). Modelling the relationship between antiretroviral treatment and HIV prevention: Limitations of the Spectrum AIDS Impact Model in a changing policy environment: African Journal of AIDS Research Vol 6(2) Aug 2007, 129-137.
 * Negredo, E., Molto, J., Puig, J., Cinquegrana, D., Bonjoch, A., Perez-Alvarez, N., et al. (2006). Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins: AIDS Vol 20(17) Nov 2006, 2159-2164.
 * Nicca, D., Moody, K., Elzi, L., & Spirig, R. (2007). Comprehensive clinical adherence interventions to enable antiretroviral therapy: A case report: JANAC: Journal of the Association of Nurses in AIDS Care Vol 18(6) Nov 2007, 44-53.
 * Nieuwkerk, P. T., Hillebrand-Haverkort, M. E., Vriesendorp, R., Jos Frissen, P. H., de Wolf, F., & Sprangers, M. A. G. (2007). Quality of life after starting highly active antiretroviral therapy for chronic HIV-1 infection at different CD4 cell counts: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 45(5) Aug 2007, 600-601.
 * Nieuwkerk, P. T., & Oort, F. J. (2005). Self-Reported Adherence to Antiretroviral Therapy for HIV-1 Infection and Virologic Treatment Response: A Meta-Analysis: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 38(4) Apr 2005, 445-448.
 * Norton, W. E., Amico, K. R., Fisher, W. A., Copenhaver, M. M., Kozal, M. J., Cornman, D. H., et al. (2008). Attitudes toward needle-sharing and HIV transmission risk behavior among HIV + injection drug users in clinical care: AIDS Care Vol 20(4) Apr 2008, 462-469.
 * Nyandiko, W. M., Ayaya, S., Nabakwe, E., Tenge, C., Sidle, J. E., Yiannoutsos, C. T., et al. (2006). Outcomes of HIV-Infected Orphaned and Non-Orphaned Children on Antiretroviral Therapy in Western Kenya: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(4) Dec 2006, 418-425.
 * Oette, M., Juretzko, P., Kroidl, A., Sagir, A., Wettstein, M., Siegrist, J., et al. (2002). Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients: AIDS Patient Care and STDs Vol 16(9) Sep 2002, 413-417.
 * Ogunro, P. S., Adeneye, A. K., Ogungbamigbe, T. O., Adewole, T. A., Musa, A. Z., & Isikwei, J. I. (2006). Perceptions of the benefits and affordability of antiretrovirals among HIV-positive persons in a rural area of South-West Nigeria: African Journal of AIDS Research Vol 5(3) 2006, 233-236.
 * Ojesina, A. I. (2008). Subtype-associated determinants of HIV-1 drug resistance (Nigeria). Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Opstelten, W., van Essen, G. A., Moons, K. G. M., van Wijck, A. J. M., Schellevis, F. G., Kalkman, C. J., et al. (2005). Do herpes zoster patients receive antivirals? A Dutch national survey in general practice: Family Practice Vol 22(5) Oct 2005, 523-528.
 * Ortiz, F., Martinez-Donate, A. P., Remor, E., Arranz, P., Bayes, R., & Hernandez-Navarro, F. (2000). Comparative study of compliance in long survival HIV+ patients with and without congenital coagulopathy: Revista Psiquis Vol 21(5) 2000, 29-38.
 * Osborn, C. Y., Paasche-Orlow, M. K., Davis, T. C., & Wolf, M. S. (2007). Health literacy: An overlooked factor in understanding HIV health disparities: American Journal of Preventive Medicine Vol 33(5) Nov 2007, 374-378.
 * Ostrop, N. J., & Gill, M. J. (2000). Antiretroviral medication adherence and persistence with respect to adherence tool usage: AIDS Patient Care and STDs Vol 14(7) Jul 2000, 351-358.
 * Ostrow, D. E., Fox, K. J., Chmiel, J. S., Silvestre, A., Visscher, B. R., Vanable, P. A., et al. (2002). Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men: AIDS Vol 16(5) Mar 2002, 775-780.
 * Paasche-Orlow, M. K., Cheng, D. M., Palepu, A., Meli, S., Faber, V., & Samet, J. H. (2006). Health Literacy, Antiretroviral Adherence, and HIV-RNA Suppression: A Longitudinal Perspective: Journal of General Internal Medicine Vol 21(8) Aug 2006, 835-840.
 * Pacifici, G. M. (2005). Pharmacokinetics of antivirals in neonate: Early Human Development Vol 81(9) Sep 2005, 773-780.
 * Palefsky, J. M., Holly, E. A., Efirdc, J. T., Da Costa, M., Jay, N., Berry, J. M., et al. (2005). Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men: AIDS Vol 19(13) Sep 2005, 1407-1414.
 * Palepu, A., Tyndall, M. W., Joy, R., Kerr, T., Wood, E., Press, N., et al. (2006). Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy: Drug and Alcohol Dependence Vol 84(2) Sep 2006, 188-194.
 * Palmisano, L., Giuliano, M., Nicastri, E., Pirillo, M. F., Andreotti, M., Galluzzo, C. M., et al. (2005). Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: The impact of highly active anti retro viral therapy: AIDS Vol 19(16) Nov 2005, 1843-1847.
 * Palombi, L., Perno, C. F., & Maria Cristina, M. (2005). HIV/AIDS in Africa: Treatment as a right and strategies for fair implementation. False assumptions on the basis of a minimalistic approach: AIDS Vol 19(5) Mar 2005, 536-537.
 * Parienti, J.-J., Massari, V., Reliquet, V., Chaillot, F., Le Moal, G., Arvieux, C., et al. (2007). Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: A randomized controlled study: Journal of Neurology, Neurosurgery & Psychiatry Vol 78(11) Nov 2007, 2217-2222.
 * Parker, M. M., Gordon, D., Reilly, A., Horowitz, H. W., Waters, M., Bennett, R., et al. (2007). Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naive, HIV-infected individuals in New York state: AIDS Patient Care and STDs Vol 21(9) Sep 2007, 644-652.
 * Park-Wyllie, L. Y., Scalera, A., Tseng, A., & Rourke, S. (2002). High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: Missed opportunities for adherence support? : AIDS Vol 16(7) May 2002, 1084-1086.
 * Park-Wyllie, L. Y., Strike, C. S., Antoniou, T., & Bayoumi, A. M. (2007). Adverse quality of life consequences of antiretroviral medications: AIDS Care Vol 19(2) Feb 2007, 252-257.
 * Parsons, G. N., Siberry, G. K., Parsons, J. K., Christensen, J. R., Joyner, M. L., Lee, S. L., et al. (2006). Multidisciplinary, Inpatient Directly Observed Therapy for HIV-1-Infected Children and Adolescents Failing HAART: A Retrospective Study: AIDS Patient Care and STDs Vol 20(4) Apr 2006, 275-284.
 * Parsons, T. D., Tucker, K. A., Hall, C. D., Robertson, W. T., Eron, J. J., Fried, M. W., et al. (2006). Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection: AIDS Vol 20(12) Aug 2006, 1591-1595.
 * Pearson, C. R., Micek, M., Simoni, J. M., Matediana, E., Martin, D. P., & Gloyd, S. (2006). Modified Directly Observed Therapy to Facilitate Highly Active Antiretroviral Therapy Adherence in Beira, Mozambique: Development and Implementation: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S134-S141.
 * Pearson, C. R., Micek, M. A., Simoni, J. M., Hoff, P. D., Matediana, E., Martin, D. P., et al. (2007). Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(2) Oct 2007, 238-244.
 * Pearson, C. R., Simoni, J. M., Hoff, P., Kurth, A. E., & Martin, D. P. (2007). Assessing antiretroviral adherence via electronic drug monitoring and self-report: An examination of key methodological issues: AIDS and Behavior Vol 11(2) Mar 2007, 161-173.
 * Pence, B. W., Miller, W. C., Gaynes, B. N., & Eron, J. J., Jr. (2007). Psychiatric Illness and Virologic Response in Patients Initiating Highly Active Antiretroviral Therapy: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 44(2) Feb 2007, 159-166.
 * Pence, B. W., Ostermann, J., Kumar, V., Whetten, K., Thielman, N., & Mugavero, M. J. (2008). The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(2) Feb 2008, 194-201.
 * Penzak, S. R., Hon, Y. Y., Lawhorn, W. D., Shirley, K. L., Spratlin, V., & Jann, M. W. (2002). Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers: Journal of Clinical Psychopharmacology Vol 22(4) Aug 2002, 366-370.
 * Peretti-Watel, P., Spire, B., Lert, F., & Obadia, Y. (2006). Drug use patterns and adherence to treatment among HIV-positive patients: Evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003): Drug and Alcohol Dependence Vol 82(Suppl 1) Apr 2006, S71-S79.
 * Perez, I. R., Blanco, J. M. S., De Labry Lima, A. O., Recio, J. M. C., Lopez, E. G., Basanta, J. J. A., et al. (2006). Factors that affect the Quality of Life of prison inmates on antiretroviral treatment: AIDS Care Vol 18(5) Jul 2006, 433-440.
 * Perez, I. R., de Labry Lima, A. O., Dominguez, C. J. D., Herrero, M. M., Roca, N. M., Liano, J. P., et al. (2005). The impact of the social support and the psychic morbidity on the quality of life of patients with antiretroviral therapy: Psicothema Vol 17(2) May 2005, 245-249.
 * Perez-Hoyos, S., Rodriguez-Arenas, M. A., De La Hera, M. G., Iribarren, J. A., Moreno, S., Viciana, P., et al. (2007). Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort: Journal of Women's Health Vol 16(7) Sep 2007, 1052-1061.
 * Persson, A., & Newman, C. (2006). Potency and vulnerability: Troubled 'selves' in the context of antiretroviral therapy: Social Science & Medicine Vol 63(6) Sep 2006, 1586-1596.
 * Petersen, M. L., Wang, Y., van der Laan, M. J., & Bangsberg, D. R. (2006). Assessing the Effectiveness of Antiretroviral Adherence Interventions: Using Marginal Structural Models to Replicate the Findings of Randomized Controlled Trials: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S96-S103.
 * Pinkerton, S. D., & Holtgrave, D. R. (1999). Combination antiretroviral therapies for HIV: Some economic considerations. Dordrecht, Netherlands: Kluwer Academic Publishers.
 * Pitts, M., Grierson, J., & Misson, S. (2005). Growing Older with HIV: A Study of Health, Social and Economic Circumstances for People Living with HIV in Australia over the Age of 50 Years: AIDS Patient Care and STDs Vol 19(7) 2005, 460-465.
 * Plana, M. T., & Blanch, J. (2007). "Azithromycin and catatonic symptoms": Drs. Plana and Blanch reply: Journal of Clinical Psychiatry Vol 68(2) Feb 2007, 337.
 * Plana, M. T., Blanch, J., Romero, S., Serra, M., & Gasto, C. (2006). Letters to the editor: Toxic Catatonia Secondary to Azithromycin: Journal of Clinical Psychiatry Vol 67(3) Mar 2006, 492-493.
 * Poizot-Manin, I., Milon, M. P., Enel, P., Gastaut, J. A., & Vion-Dury, J. (2005). Discrepancy between Blood and Cerebral Didanosine Effects in HIV Patients: A Magnetic Resonance Spectroscopy Study: European Neurology Vol 53(4) Jul 2005, 223-225.
 * Poundstone, K. E., Chaisson, R. E., & Moore, R. D. (2001). Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy: AIDS Vol 15(9) Jun 2001, 1115-1123.
 * Power, R., Koopman, C., Volk, J., Israelski, D. M., Stone, L., Chesney, M. A., et al. (2003). Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected persons: AIDS Patient Care and STDs Vol 17(5) May 2003, 245-252.
 * Preau, M., Bouhnik, A.-D., Poizot-Martin, I., Protopopescu, C., Carrieri, M.-P., Gallais, H., et al. (2007). Determinants of depressive symptomatology among HIV patients infected by injecting drug use on the maintenance phase of HAART: Alcoologie et Addictologie Vol 29(2) Jun 2007, 161-169.
 * Probasco, J. C., Spudich, S. S., Critchfield, J., Lee, E., Lollo, N., Deeks, S. G., et al. (2008). Failure of atorvastatin to modulate CSF HIV-1 infection: Results of a pilot study: Neurology Vol 71(7) Aug 2008, 521-524.
 * Protopopescu, C., Marcellin, F., Spire, B., Preau, M., Verdon, R., Peyramond, D., et al. (2007). Health-related quality of life in HIV-1-infected patients on HAART: A five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8): Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation Vol 16(4) May 2007, 577-591.
 * Puccio, J. A., Belzer, M., Olson, J., Martinez, M., Salata, C., Tucker, D., et al. (2006). The Use of Cell Phone Reminder Calls for Assisting HIV-Infected Adolescents and Young Adults to Adhere to Highly Active Antiretroviral Therapy: A Pilot Study: AIDS Patient Care and STDs Vol 20(6) Jun 2006, 438-444.
 * Puga, A. M. (2006). Adherence in the Pediatric HIV Population: Beal, Jeffrey (Ed); Orrick, Joanne J (Ed); Alfonso, Kimberly (Ed).
 * Pugatch, D., Bennett, L., & Patterson, D. (2002). HIV medication adherence in adolescents: A qualitative study: Journal of HIV/AIDS Prevention & Education for Adolescents & Children Vol 5(1-2) 2002, 9-29.
 * Quiros-Roldan, E., Torti, C., Lapadula, G., Ladisa, N., Micheli, V., Patroni, A., et al. (2007). Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy: AIDS Patient Care and STDs Vol 21(2) Feb 2007, 92-99.
 * Rabkin, J. G., & Ferrando, S. (1997). A "second life" agenda: Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome: Archives of General Psychiatry Vol 54(11) Nov 1997, 1049-1053.
 * Rabkin, J. G., Ferrando, S. J., Lin, S.-H., Sewell, M., & McElhiney, M. (2000). Psychological effects of HAART: A 2-year study: Psychosomatic Medicine Vol 62(3) May-Jun 2000, 413-422.
 * Raines, C., Radcliffe, O., & Treisman, G. J. (2005). Neurologic and Psychiatric Complications of Antiretroviral Agents: JANAC: Journal of the Association of Nurses in AIDS Care Vol 16(5) Sep-Oct 2005, 35-48.
 * Rainey, P. M., Friedland, G. H., Snidow, J. W., McCance-Katz, E. F., Mitchell, S. M., Andrews, L., et al. (2002). The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects: The American Journal on Addictions Vol 11(1) Win 2002, 66-74.
 * Raison, C. L., Broadwell, S. D., Borisov, A. S., Manatunga, A. K., Capuron, L., Woolwine, B. J., et al. (2005). Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C: Brain, Behavior, and Immunity Vol 19(1) Jan 2005, 23-27.
 * Raison, C. L., Capuron, L., & Miller, A. H. (2005). Depressive symptoms and viral clearance: In response: Brain, Behavior, and Immunity Vol 19(4) Jul 2005, 273-274.
 * Reedijk, M., Wigersma, L., & Mohrs, J. (1998). When do HIV-infected persons start with antiretroviral therapy? A retrospective analysis of patients' monitoring and treatment status in general practice, as compared with the 1991 Dutch HIV treatment guidelines: Family Practice Vol 15(6) Dec 1998, 525-528.
 * Remien, R. H., Bastos, F. I., Terto, V., Jr., Raxach, J. C., Pinto, R. M., Parker, R. G., et al. (2007). Adherence to antiretroviral therapy in a context of universal access, in Rio de Janeiro, Brazil: AIDS Care Vol 19(6) Jul 2007, 740-748.
 * Remien, R. H., Exner, T. M., Morin, S. F., Ehrhardt, A. A., Johnson, M. O., Correale, J., et al. (2007). Medication adherence and sexual risk behavior among HIV-infected adults: Implications for transmission of resistant virus: AIDS and Behavior Vol 11(5) Sep 2007, 663-675.
 * Remien, R. H., Stirratt, M. J., Dognin, J., Day, E., El-Bassel, N., & Warne, P. (2006). Moving from Theory to Research to Practice: Implementing an Effective Dyadic Intervention to Improve Antiretroviral Adherence for Clinic Patients: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S69-S78.
 * Remor, E. (2002). Assessment of adherence to antiretroviral therapy in HIV+ patients: Psicothema Vol 14(2) May 2002, 262-267.
 * Rey, D., Bendiane, M. K., Bouhnik, A.-D., Almeda, J., Moatti, J. P., & Carrieri, M. P. (2008). Physicians' and patients' adherence to antiretroviral prophylaxis after sexual exposure to HIV: Results from South-Eastern France: AIDS Care Vol 20(5) May 2008, 537-541.
 * Reynolds, N. R. (2003). The problem of antiretroviral adherence: A self-regulatory model for intervention: AIDS Care Vol 15(1) Feb 2003, 117-124.
 * Reynolds, N. R., & Neidig, J. L. (2002). Characteristics of nausea reported by HIV-infected patients initiating combination antiretroviral regimens: Clinical Nursing Research Vol 11(1) Feb 2002, 71-88.
 * Reynolds, N. R., Testa, M. A., Marc, L. G., Chesney, M. A., Neidig, J. L., Smith, S. R., et al. (2004). Factors Influencing Medication Adherence Beliefs and Self-Efficacy in Persons Naive to Antiretroviral Therapy: A Multicenter, Cross-Sectional Study: AIDS and Behavior Vol 8(2) Jun 2004, 141-150.
 * Reynolds, N. R., Testa, M. A., Su, M., Chesney, M. A., Neidig, J. L., Frank, I., et al. (2008). Telephone support to improve antiretroviral medication adherence: A multisite, randomized controlled trial: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 47(1) Jan 2008, 62-68.
 * Ricceri, L., Venerosi, A., Valanzano, A., Sorace, A., & Alleva, E. (2001). Prenatal AZT or 3TC and mouse development of locomotor activity and hot-plate responding upon administration of the GABA-sub(A ) receptor agonist muscimol: Psychopharmacology Vol 153(4) Feb 2001, 434-442.
 * Richardson, J. L., Martin, E. M., Jimenez, N., Danley, K., Cohen, M., Carson, V. L., et al. (2002). Neuropsychological functioning in a cohort of HIV infected women: Importance of antiretroviral therapy: Journal of the International Neuropsychological Society Vol 8(6) Sep 2002, 781-793.
 * Richardson, J. L., Martin, E. M., Jimenez, N., Danley, K., Cohen, M., Carson, V. L., et al. (2005). "Neuropsychological functioning in a cohort of HIV infected women: Importance of antiretroviral therapy": Erratum: Journal of the International Neuropsychological Society Vol 11(1) Jan 2005, 120.
 * Richter, D. L., Sowell, R. L., & Pluto, D. M. (2002). Attitudes toward antiretroviral therapy among African American women: American Journal of Health Behavior Vol 26(1) Jan-Feb 2002, 25-33.
 * Roberts, K. J. (2005). Barriers to Antiretroviral Medication Adherence in Young HIV-Infected Children: Youth & Society Vol 37(2) Dec 2005, 230-245.
 * Roberts, K. J., & Mann, T. (2000). Barriers to antiretroviral medication adherence in HIV-infected women: AIDS Care Vol 12(4) Aug 2000, 377-386.
 * Roberts, K. J., & Mann, T. (2003). Adherence to antiretroviral medications in HIV/AIDS care: A narrative exploration of one woman's foray into intentional nonadherence: Health Care for Women International Vol 24(6) Jul 2003, 552-564.
 * Roberts, K. J., & Volberding, P. (1999). Adherence communication: A qualitative analysis of physician-patient dialogue: AIDS Vol 13(13) Sep 1999, 1771-1778.
 * Robertson, K. R., Smurzynski, M., Parsons, T. D., Wu, K., Bosch, R. J., Wu, J., et al. (2007). The prevalence and incidence of neurocognitive impairment in the HAART era: AIDS Vol 21(14) Sep 2007, 1915-1921.
 * Rogers, A. S., Miller, S., Murphy, D. A., Tanney, M., & Fortune, T. (2001). The TREAT (Therapeutic Regimens Enhancing Adherence in Teens) Program: Theory and preliminary results: Journal of Adolescent Health Vol 29(Suppl3) Sep 2001, 30-38.
 * Rosen, M. I., Rigsby, M. O., Dieckhaus, K. D., & Cramer, J. A. (2003). Effects of Illicit Drug Use on Adherence to Prescribed Antiretroviral Medication: The American Journal on Addictions Vol 12(5) Oct-Dec 2003, 455-458.
 * Rothenberg, R., Campos, P. E., del Rio, C., Johnson, W., Arriola, K. J., & Brown, M. (2003). Once and future HIV treatment: A comparison of clinic and community groups: International Journal of STD & AIDS Vol 14(7) Jul 2003, 438-447.
 * Rusch, M., Nixon, S., Schilder, A., Braitstein, P., Chan, K., & Hogg, R. S. (2004). Use of antiretroviral therapy among HIV positive individuals living in British Columbia: AIDS Care Vol 16(7) Oct 2004, 914-922.
 * Russell, S., Seeley, J., Ezati, E., Wamai, N., Were, W., & Bunnell, R. (2007). Coming back from the dead: Living with HIV as a chronic condition in rural Africa: Health Policy and Planning Vol 22(5) Aug 2007, 344-347.
 * Ryan, G. W., & Wagner, G. J. (2003). Pill taking 'routinization': A critical factor to understanding episodic medication adherence: AIDS Care Vol 15(6) Dec 2003, 795-806.
 * Rybakowski, J. K. (1999). The effect of lithium on the immune system: Human Psychopharmacology: Clinical and Experimental Vol 14(5) Jul 1999, 345-353.
 * Sabato, S., Wesselingh, S., Fuller, A., Ray, J., & Mijch, A. (2002). Efavirenz-induced catatonia: AIDS Vol 16(13) Sep 2002, 1841-1842.
 * Sacktor, N., Lyles, R. H., Skolasky, R. L., Anderson, D. E., McArthur, J. C., McFarlane, G., et al. (1999). Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men: Neurology Vol 52(8) May 1999, 1640-1647.
 * Sacktor, N., Skolasky, R. L., Tarwater, P. M., McArthur, J. C., Selnes, O. A., Becker, J., et al. (2003). Response to systemic HIV viral load suppression correlates with psychomotor speed performance: Neurology Vol 61(4) Aug 2003, 567-569.
 * Safren, S. A., Hendriksen, E. S., Desousa, N., Boswell, S. L., & Mayer, K. H. (2003). Use of an on-line pager system to increase adherence to antiretroviral medications: AIDS Care Vol 15(6) Dec 2003, 787-793.
 * Safren, S. A., Hendriksen, E. S., Mayer, K. H., Mimiaga, M. J., Pickard, R., & Otto, M. W. (2004). Cognitive-Behavioral Therapy for HIV Medication Adherence and Depression: Cognitive and Behavioral Practice Vol 11(4) Fal 2004, 415-424.
 * Samarasinghe, Y. P. (2007). HIV and diabetes: Primary Care Diabetes Vol 1(2) Jun 2007, 99-101.
 * Sampaio-Sa, M., Page-Shafer, K., Bangsberg, D. R., Evans, J., Dourado, M. d. L., Teixeira, C., et al. (2008). 100% adherence study: Educational workshops vs. video sessions to improve adherence among ART-naive patients in Salvador, Brazil: AIDS and Behavior Vol 12(Suppl 1) Jul 2008, S54-S62.
 * Sankar, A., Golin, C., Simoni, J. M., Luborsky, M., & Pearson, C. (2006). How Qualitative Methods Contribute to Understanding Combination Antiretroviral Therapy Adherence: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S54-S68.
 * Sankar, A., Wunderlich, T., Neufeld, S., & Luborsky, M. (2007). Sero-positive African Americans' beliefs about alcohol and their impact on anti-retroviral adherence: AIDS and Behavior Vol 11(2) Mar 2007, 195-203.
 * Sankar, A. P., Nevedal, D. C., Neufeld, S., & Luborsky, M. R. (2007). What is a missed dose? Implications for construct validity and patient adherence: AIDS Care Vol 19(6) Jul 2007, 775-780.
 * Sansom, S. L., Anthony, M. N., Garland, W. H., Squires, K. E., Witt, M. D., Kovacs, A. A., et al. (2008). The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization: AIDS Patient Care and STDs Vol 22(2) Feb 2008, 131-138.
 * Santoro, N., Arnsten, J. H., Buono, D., Howard, A. A., & Schoenbaum, E. E. (2005). Impact of Street Drug Use, HIV Infection, and Highly Active Antiretroviral Therapy on Reproductive Hormones in Middle-Aged Women: Journal of Women's Health Vol 14(10) Dec 2005, 898-905.
 * Santos, C. Q., Adeyemi, O., & Tenorio, A. R. (2006). Attitudes toward directly administered antiretroviral therapy (DAART) among HIV-positive inpatients in an inner city public hospital: AIDS Care Vol 18(7) Oct 2006, 808-811.
 * Sanz de la Garza, C. L., Paoletti-Duarte, S., Garcia-Martin, C., & Gutierrez-Casares, J. R. (2001). Efavirenz-induced psychosis: AIDS Vol 15(14) Sep 2001, 1911-1912.
 * Saracino, A., El-Hamad, I., Prato, R., Cibelli, D. C., Tartaglia, A., Palumbo, E., et al. (2005). Access to HAART in HIV-Infected Immigrants: A Retrospective Multicenter Italian Study: AIDS Patient Care and STDs Vol 19(9) Sep 2005, 599-606.
 * Savini, C. J., James, C. W., & DiGuglielmo, D. J. (2003). Survey of Patient and Clinician Attitudes on Adherence in a Rural HIV Clinic: JANAC: Journal of the Association of Nurses in AIDS Care Vol 14(3) May-Jun 2003, 72-75.
 * Sax, P. E., & Gathe, J. C., Jr. (2005). Beyond Efficacy: The Impact of Combination Antiretroviral Therapy on Quality of Life: AIDS Patient Care and STDs Vol 19(9) Sep 2005, 563-576.
 * Schackman, B. R., Ribaudo, H. J., Krambrink, A., Hughes, V., Kuritzkes, D. R., & Gulick, R. M. (2007). Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: Results of ACTG A5095: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(5) Dec 2007, 547-554.
 * Schoesson, L. N., Williams, M. L., Ross, M. W., Bratt, G., & Keel, B. (2007). Factors associated with suboptimal antiretroviral therapy adherence to dose, schedule, and dietary instructions: AIDS and Behavior Vol 11(2) Mar 2007, 175-183.
 * Schonnesson, L. N., Diamond, P. M., Ross, M. W., Williams, M., & Bratt, G. (2006). Baseline predictors of three types of antiretroviral therapy (ART) adherence: A 2-year follow-up: AIDS Care Vol 18(3) Apr 2006, 246-253.
 * Schonnesson, L. N., Diamond, P. M., Ross, M. W., Williams, M., & Bratt, G. (2006). "Baseline predictors of three types of antiretroviral therapy (ART) adherence: A 2-year follow-up": Erratum: AIDS Care Vol 18(4) May 2006, 407-414.
 * Schrimshaw, E. W., Siegel, K., & Lekas, H.-M. (2005). Changes in attitudes toward antiviral medication: A comparison of women living with HIV/AIDS in the pre-HAART and HAART eras: AIDS and Behavior Vol 9(3) Sep 2005, 267-279.
 * Schroeder, J. R., Latkin, C. A., Hoover, D. R., Knowlton, A. R., Zenilman, J., Strathdee, S., et al. (2001). Social factors related to antiretroviral therapy use in injection drug users: AIDS and Behavior Vol 5(4) Dec 2001, 363-369.
 * Schuman, P., Ohmit, S. E., Cohen, M., Sacks, H. S., Richardson, J., Young, M., et al. (2001). Prescription of and adherence to antiretroviral therapy among women with AIDS: AIDS and Behavior Vol 5(4) Dec 2001, 371-378.
 * Schwarz, D. F., Henry-Reid, L., Houser, J., & Ma, Y. (2001). The association of perceived health, clinical status, and initiation of HAART (highly active antiretroviral therapy) in adolescents: Journal of Adolescent Health Vol 29(Suppl3) Sep 2001, 115-122.
 * Seeley, J. A., & Allison, E. H. (2005). HIV/AIDS in fishing communities: Challenges to delivering antiretroviral therapy to vulnerable groups: AIDS Care Vol 17(6) Aug 2005, 688-697.
 * Selwyn, P. A. (2005). Palliative Care for Patient with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome: Journal of Palliative Medicine Vol 8(6) Dec 2005, 1248-1268.
 * Sension, M. G., Farthing, C., Shaffer, A. G., Graham, E., Siemon-Hryczyk, P., & Pilson, R. S. (2001). Challenges of antiretroviral treatment in transient and drug-using populations: The SUN study: AIDS Patient Care and STDs Vol 15(3) Mar 2001, 129-136.
 * Seoane-Vazquez, E., & Rodriguez-Monguio, R. (2007). Negotiating antiretroviral drug prices: The experience of the Andean countries: Health Policy and Planning Vol 22(2) Mar 2007, 63-72.
 * Seyler, C., Adje-Toure, C., Messou, E., Dakoury-Dogbo, N., Rouet, F., Gabillard, D., et al. (2007). Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa: AIDS Vol 21(9) May 2007, 1157-1164.
 * Shaw, R. R. (2007). The relationship between pediatric HIV infection, CD4 percentage, HAART, and WISC-III performance. Dissertation Abstracts International Section A: Humanities and Social Sciences.
 * Shelon, J. D., & Peterson, E. A. (2004). The imperative for family planning in ART in Africa: Lancet Vol 364(9449) Nov 2004, 1916-1918.
 * Sherer, R. D., Jr., Fath, M. J., Da Silva, B. A., Nicolau, A.-M., & Miller, N. L. (2005). The Importance of Potency and Durability in HIV Patient Antiretroviral Therapy Preferences: A Telephone Survey: AIDS Patient Care and STDs Vol 19(12) Dec 2005, 794-802.
 * Sherr, L., Lampe, F., Norwood, S., Date, H. L., Harding, R., Johnson, M., et al. (2008). Adherence to antiretroviral treatment in patients with HIV in the UK: A study of complexity: AIDS Care Vol 20(4) Apr 2008, 442-448.
 * Sherr, L., Lampe, F., Norwood, S., Leake-Date, H., Fisher, M., Edwards, S., et al. (2007). Successive switching of antiretroviral therapy is associated with high psychological and physical burden: International Journal of STD & AIDS Vol 18(10) Oct 2007, 700-704.
 * Shiraki, K., Andoh, T., Imakita, M., Kurokawa, M., Kuraishi, Y., Niimura, M., et al. (1998). Caffeine inhibits paresthesia induced by herpes simplex virus through action on primary sensory neurons in rats: Neuroscience Research Vol 31(3) Jul 1998, 235-240.
 * Sian, A. K. (2001). Encouraging adherence to antiretroviral drug regimes: Family Practice Vol 18(4) Aug 2001, 463.
 * Sidat, M., Rawstorne, P., Lister, N., & Fairley, C. K. (2006). Association between risk of acquiring HIV and beliefs and perceptions about the lived experience of HIV/AIDS among HIV-negative or untested men who have sex with men: AIDS Care Vol 18(8) Nov 2006, 934-941.
 * Siegel, K., Karus, D., & Schrimshaw, E. W. (2000). Racial differences in attitudes toward protease inhibitors among older HIV-infected men: AIDS Care Vol 12(4) Aug 2000, 423-434.
 * Siegel, K., & Schrimshaw, E. W. (2005). Stress, appraisal, and coping: A comparison of HIV-infected women in the pre-HAART and HAART eras: Journal of Psychosomatic Research Vol 58(3) Mar 2005, 225-233.
 * Siegel, K., Schrimshaw, E. W., & Raveis, V. H. (2000). Accounts for non-adherence to antiviral combination therapies among older HIV-infected adults: Psychology, Health & Medicine Vol 5(1) Feb 2000, 29-42.
 * Silverberg, M. J., Wegner, S. A., Milazzo, M. J., McKaig, R. G., Williams, C. F., Agan, B. K., et al. (2006). Effectiveness of highly-active antiretroviral therapy by race/ethnicity: AIDS Vol 20(11) Jul 2006, 1531-1538.
 * Simins, B., & Lucchesi, C. (1999). Effortless unintentional smoking cessation after lamivudine-zidovudine-indinavir postexposure anti-HIV chemoprophylaxis: Addiction Vol 94(1) Jan 1999, 139-140.
 * Simoni, J. M., Frick, P. A., Lockhart, D., & Liebovitz, D. (2002). Mediators of social support and antiretroviral adherence among an indigent population in New York City: AIDS Patient Care and STDs Vol 16(9) Sep 2002, 431-439.
 * Simoni, J. M., Pearson, C. R., Pantalone, D. W., Marks, G., & Crepaz, N. (2006). Efficacy of Interventions in Improving Highly Active Antiretroviral Therapy Adherence and HIV-1 RNA Viral Load: A Meta-Analytic Review of Randomized Controlled Trials: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S23-S35.
 * Singh, D., & Goodkin, K. (2007). Psychopharmacologic treatment responses to HIV-infected patients to antipsychotic medications: Journal of Clinical Psychiatry Vol 68(4) Apr 2007, 631-632.
 * Skhosana, N. L., Struthers, H., Gray, G. E., & McLntyre, J. A. (2006). HIV disclosure and other factors that impact on adherence to antiretroviral therapy: The case of Soweto, South Africa: African Journal of AIDS Research Vol 5(1) 2006, 17-26.
 * Smit, E., Crespo, C. J., Semba, R. D., Jaworowicz, D., Vlahov, D., Ricketts, E. P., et al. (2006). Physical activity in a cohort of HIV-positive and HIV-negative injection drug users: AIDS Care Vol 18(8) Nov 2006, 1040-1045.
 * Smith, C. J., Sabin, C. A., Youle, M. S., Lampe, F. C., Bhagani, S., Madge, S., et al. (2007). Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: The role of gender: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(1) Sep 2007, 62-67.
 * Smith, D., Goggin, L., Meldrum, H., Phillips, S., Russell, D., Bloch, M., et al. (2000). Capturing the paradigm shift in HIV treatment: Changing attitudes in the choice of combination antiretroviral drugs by high HIV caseload Australian GPs (1996-1997): AIDS Care Vol 12(1) Feb 2000, 41-47.
 * Smith, R. A., & Siplon, P. D. (2006). Drugs into bodies: Global AIDS treatment activism. Westport, CT: Praeger Publishers/Greenwood Publishing Group.
 * Smith-Rohrberg, D., Mezger, J., Walton, M., Bruce, R. D., & Altice, F. L. (2006). Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(Suppl1) Dec 2006, S48-S53.
 * Snell, C. R., Stevens, S. R., & VanNess, J. M. (2001). Chronic fatigue syndrome, ampligen, and quality of life: A phenomenological perspective: Journal of Chronic Fatigue Syndrome Vol 8(3-4) 2001, 117-121.
 * Sodergard, B., Hofer, S., Halvarsson, M., Sonnerborg, A., Tully, M. P., & Lindblad, A. K. (2007). A structural equation modeling approach to the concepts of adherence and readiness in antiretroviral treatment: Patient Education and Counseling Vol 67(1-2) Jul 2007, 108-116.
 * Sollitto, S., Mehlman, M., Youngner, S., & Lederman, M. M. (2001). Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment? : AIDS Vol 15(2) Jan 2001, 153-159.
 * Soria, A., & Lazzarin, A. (2007). Antiretroviral treatment strategies and immune reconstitution in treatment-naive HIV-infected patients with advanced disease: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(Suppl1) Sep 2007, S19-S30.
 * Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., Moatti, J.-P., et al. (2002). Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach: Social Science & Medicine Vol 54(10) May 2002, 1481-1496.
 * Stall, R., Pollack, L., Mills, T. C., Martin, J. N., Osmond, D., Paul, J., et al. (2001). Use of antiretroviral therapies among HIV-infected men who have sex with men: A household-based sample of 4 major American cities: American Journal of Public Health Vol 91(5) May 2001, 767-773.
 * Stankoff, B., Tourbah, A., Suarez, S., Turell, E., Stievenart, J. L., Payan, C., et al. (2001). Clinical and spectroscopic improvement in HIV-associated cognitive impairment: Neurology Vol 56(1) Jan 2001, 112-115.
 * Starace, F., Massa, A., Amico, K. R., & Fisher, J. D. (2006). Adherence to antiretroviral therapy: An empirical test of the information-motivation-behavioral skills model: Health Psychology Vol 25(2) Mar 2006, 153-162.
 * Starks, H., Simoni, J., Zhao, H., Huang, B., Fredriksen-Goldsen, K., Pearson, C., et al. (2008). Conceptualizing antiretroviral adherence in Beijing, China: AIDS Care Vol 20(6) Jul 2008, 607-614.
 * Staszewski, S., Miller, V., Rehmet, S., Stark, T., & et al. (1996). Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients: AIDS Vol 10(5) May 1996, F1-F7.
 * Steele, R. G., Anderson, B., Rindel, B., Dreyer, M. L., Perrin, K., Christensen, R., et al. (2001). Adherence to antiretroviral therapy among HIV-positive children: Examination of the role of caregiver health beliefs: AIDS Care Vol 13(5) Oct 2001, 617-629.
 * Steele, R. G., & Grauer, D. (2003). Adherence to antiretroviral therapy for pediatric HIV infection: Review of the literature and recommendations for research: Clinical Child and Family Psychology Review Vol 6(1) Mar 2003, 17-30.
 * Stein, J., Lewin, S., & Fairall, L. (2007). Hope is the pillar of the universe: Health-care providers' experiences of delivering anti-retroviral therapy in primary health-care clinics in the Free State province of South Africa: Social Science & Medicine Vol 64(4) Feb 2007, 954-964.
 * Stein, M. D., Urdaneta, M. E., Clarke, J., Maksad, J., Sobota, M., Hanna, L., et al. (2000). Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance: Journal of Addictive Diseases Vol 19(1) 2000, 85-94.
 * Stewart, C., & Alfonso, R. (2006). Oral Manifestations: Beal, Jeffrey (Ed); Orrick, Joanne J (Ed); Alfonso, Kimberly (Ed).
 * Stirratt, M. J., Remien, R. H., Smith, A., Copeland, O. Q., Dolezal, C., & Krieger, D. (2006). The Role of HIV Serostatus Disclosure in Antiretroviral Medication Adherence: AIDS and Behavior Vol 10(5) Sep 2006, 483-493.
 * Suarez, S., Baril, L., Stankoff, B., Khellaf, M., Dubois, B., Lubetzki, C., et al. (2001). Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy: AIDS Vol 15(2) Jan 2001, 195-200.
 * Teerawattananon, Y., Hanshaoworakul, W., Russell, S., Tangcharoensathien, V., & Jiamton, S. (2006). Targeting Antiretroviral Therapy: Lessons from a Longitudinal Study of Morbidity and Treatment in Relation to CD4 Count in Thailand: Asia-Pacific Journal of Public Health Vol 18(1) 2006, 39-48.
 * Tegger, M. K., Crane, H. M., Tapia, K. A., Uldall, K. K., Holte, S. E., & Kitahata, M. M. (2008). The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-injected individuals: AIDS Patient Care and STDs Vol 22(3) Mar 2008, 233-243.
 * Temmerman, M., Quaghebeur, A., Mwanyumba, F., & Mandaliya, K. (2003). Mother-to-child HIV transmission in resource poor settings: How to improve coverage? : AIDS Vol 17(8) May 2003, 1239-1242.
 * The, A., Mitty, J. A., Loewenthal, H., Bazerman, L. B., & Flanigan, T. (2005). The Potential Use of Directly Observed Therapy (DOT) for the Treatment of HIV-positive Individuals Being Released From Prison: Journal of Correctional Health Care Vol 11(2) Apr 2005, 191-198.
 * Theall, K. P., Clark, R. A., Powell, A., Smith, H., & Kissinger, P. (2007). Alcohol consumption, art usage and high-risk sex among women infected with HIV: AIDS and Behavior Vol 11(2) Mar 2007, 205-215.
 * Thompson, M. (2006). Antiretroviral Drug Interactions: Beal, Jeffrey (Ed); Orrick, Joanne J (Ed); Alfonso, Kimberly (Ed).
 * Thompson, M., & Glaser, V. (2005). Studying the Potential of Tenofovir to Prevent Sexual Transmission of HIV: First Steps: AIDS Patient Care and STDs Vol 19(1) Jan 2005, 1-4.
 * Tippett Barr, B. A. (2007). Pediatric antiretroviral adherence and child disclosure in Botswana. Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Touloumi, G., Pantazis, N., Antoniou, A., Stirnadel, H. A., Walker, S. A., & Porter, K. (2006). Highly Active Antiretroviral Therapy Interruption: Predictors and Virologic and Immunologic Consequences: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 42(5) Aug 2006, 554-561.
 * Tozzi, V., Balestra, P., Bellagamba, R., Corpolongo, A., Salvatori, M. F., Visco-Comandini, U., et al. (2007). Persistence of neuropsychological deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: Prevalence and risk factors: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 45(2) Jun 2007, 174-182.
 * Tozzi, V., Balestra, P., Galgani, S., Narciso, P., Ferri, F., Sebastiani, G., et al. (1999). Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment: AIDS Vol 13(14) Oct 1999, 1889-1897.
 * Tozzi, V., Balestra, P., Murri, R., Galgani, S., Bellagamba, R., Narciso, P., et al. (2004). Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART: International Journal of STD & AIDS Vol 15(4) Apr 2004, 254-259.
 * Tozzi, V., Balestra, P., & Salvatori, M. F. (2007). Authors' response to Biscione: "Estimating the risk of persistent neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment." JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(4) Dec 2007, 510-512.
 * Treisman, G. (2007). The Necessary Birth of AIDS Activism: PsycCRITIQUES Vol 52 (33), 2007.
 * Treisman, G. J., & Kaplin, A. I. (2002). Neurologic and psychiatric complications of antiretroviral agents: AIDS Vol 16(9) Jun 2002, 1201-1215.
 * Treluyer, J.-M., Chappuy, H., Rey, E., Blanche, S., & Pons, G. (2002). The pharmacology of antiretroviral drugs in pediatric patients: Current Therapeutic Research Vol 63(10) Oct 2002, 682-694.
 * Trocello, J. M., Blanchet, A., Bourdain, F., Meyohas, M. C., & Vidailhet, M. (2006). Resolution of choreic movements associated with HIV encephalitis with anti-retroviral therapy: Revue Neurologique Vol 162(1) Jan 2006, 89-91.
 * Trotta, M. P., Ammassari, A., Cozzi-Lepri, A., Zaccarelli, M., Castelli, F., Narciso, P., et al. (2003). Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens: AIDS Vol 17(7) May 2003, 1099-1102.
 * Tsasis, P. (2000). Health-related quality-of-life measurements in HIV/AIDS care: AIDS Patient Care and STDs Vol 14(8) Aug 2000, 427-438.
 * Tsasis, P. (2001). Adherence assessment to highly active antiretroviral therapy: AIDS Patient Care and STDs Vol 15(3) Mar 2001, 109-115.
 * Tucker, J. S., Orlando, M., Burnam, M. A., Sherbourne, C. D., Kung, F.-Y., & Gifford, A. L. (2004). Psychosocial Mediators of Antiretroviral Nonadherence in HIV-Positive Adults With Substance Use and Mental Health Problems: Health Psychology Vol 23(4) Jul 2004, 363-370.
 * Tugenberg, T., Ware, N. C., & Wyatt, M. A. (2006). Paradoxical Effects of Clinician Emphasis on Adherence to Combination Antiretroviral Therapy for HIV/AIDS: AIDS Patient Care and STDs Vol 20(4) Apr 2006, 269-274.
 * Tuldra, A., Fumaz, C. R., Ferrer, M. J., Paredes, R., Romeu, J., Ruiz, L., et al. (2001). Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads: AIDS Vol 15(14) Sep 2001, 1904-1906.
 * Turner, B. J., Fleishman, J. A., Wenger, N., London, A. S., Burnam, M. A., Shapiro, M. F., et al. (2001). Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons: Journal of General Internal Medicine Vol 16(9) Sep 2001, 625-633.
 * Turner, B. J., Newschaffer, C. J., Zhang, D., Cosler, L., & Hauck, W. W. (2000). Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women: Medical Care Vol 38(9) Sep 2000, 911-925.
 * Ubbiali, A., Donati, D., Chiorri, C., Bregani, V., Cattaneo, E., Maffei, C., et al. (2008). Prediction of adherence to antiretroviral therapy: Can patients' gender play some role? An Italian pilot study: AIDS Care Vol 20(5) May 2008, 571-575.
 * Ubbiali, A., Donati, D., Chiorri, C., Bregani, V., Cattaneo, E., Maffei, C., et al. (2008). The usefulness of the Multidimensional Health Locus of Control Form C (MHLC-C) for HIV + subjects: An Italian study: AIDS Care Vol 20(4) Apr 2008, 495-502.
 * Unge, C., Johansson, A., Zachariah, R., Some, D., Van Engelgem, I., & Ekstrom, A. M. (2008). Reasons for unsatisfactory acceptance of antiretroviral treatment in the urban Kibera slum, Kenya: AIDS Care Vol 20(2) Feb 2008, 146-149.
 * Utley, T. F. M., Ogden, J. A., Gibb, A., McGrath, N., & Anderson, N. E. (1997). The long-term neuropsychological outcome of herpes simplex encephalitis in a series of unselected survivors: Neuropsychiatry, Neuropsychology, & Behavioral Neurology Vol 10(3) Jul 1997, 180-189.
 * van Asten, L. C., Boufassa, F., Schiffer, V., Brettle, R. P., Robertson, J. R., Aguado, I. H., et al. (2003). Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level: European Journal of Public Health Vol 13(4) Dec 2003, 347-349.
 * van der Merwe, K., Chersich, M. F., Technau, K., Umurungi, Y., Conradie, F., & Coovadia, A. (2006). Integration of Antiretroviral Treatment Within Antenatal Care in Gauteng Province, South Africa: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 43(5) Dec 2006, 577-581.
 * van der Werf, M. J., Schinkel, J., van Santen, G., Vergouwe, I., Wix, R. A., & van Ameijden, E. J. (1999). Highly active antiretroviral therapy among drug users in Amsterdam: Self-perceived reasons for not receiving therapy: AIDS Vol 13(10) Jul 1999, 1280-1281.
 * Van Dun, R. E., Derix, M. M., Van Dam, F. S., & Portegies, P. (1994). Cognitive functions, survival time and mood of patients with AIDS and ARC: Gedrag & Gezondheid: Tijdschrift voor Psychologie en Gezondheid Vol 22(1) Jan 1994, 16-25.
 * van Oosterhout, J. J. G., Kumwenda, J. K., Hartung, T., Mhango, B., & Zijlstra, E. E. (2007). Can the initial success of the Malawi ART scale-up programme be sustained? The example of Queen Elizabeth Central Hospital, Blantyre: AIDS Care Vol 19(10) 2007, 1241-1246.
 * Vaz, M. J. R., Barros, S. M. O., Palacios, R., Senise, J. F., Lunardi, L., Amed, A. M., et al. (2007). HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women: International Journal of STD & AIDS Vol 18(1) Jan 2007, 28-32.
 * Vijayaraghavan, A., Efrusy, M. B., Mazonson, P. D., Ebrahim, O., Sanne, I. M., & Santas, C. C. (2007). Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(1) Sep 2007, 91-100.
 * Vincke, J., & Bolton, R. (2002). Therapy adherence and highly active antiretroviral therapy: Comparison of three sources of information: AIDS Patient Care and STDs Vol 16(10) Oct 2002, 487-495.
 * Voetsch, A. C., Heffelfinger, J. D., Begley, E. B., Jafa-Bhushan, K., & Sullivan, P. S. (2007). Knowledge and use of preexposure and postexposure prophylaxis among attendees of Minority Gay Pride events, 2005 through 2006: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 46(3) Nov 2007, 378-380.
 * Voils, C. I., Barroso, J., Hasselblad, V., & Sandelowski, M. (2007). In or out? Methodological considerations for including and excluding findings from a meta-analysis of predictors of antiretroviral adherence in HIV-positive women: Journal of Advanced Nursing Vol 59(2) Jul 2007, 163-177.
 * Volberding, P. A. (2003). HIV therapy in 2003: consensus and controversy: AIDS Vol 17(Suppl1) Apr 2003, S4-S11.
 * von Giesen, H.-J., Wittsack, H.-J., Wenserski, F., Koller, H., Hefter, H., & Arendt, G. (2001). Basal ganglia metabolite abnormalities in minor motor disorders associated with human immunodeficiency virus type 1: Archives of Neurology Vol 58(8) Aug 2001, 1281-1286.
 * Waddell, E. N., & Messeri, P. A. (2006). Social Support, Disclosure, and Use of Antiretroviral Therapy: AIDS and Behavior Vol 10(3) May 2006, 263-272.
 * Wagner, G. J. (2002). Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries: AIDS Patient Care and STDs Vol 16(12) Dec 2002, 599-608.
 * Wagner, G. J., Kanouse, D. E., Golinelli, D., Miller, L. G., Daar, E. S., Witt, M. D., et al. (2006). Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: A randomized controlled trial (CCTG 578): AIDS Vol 20(9) Jun 2006, 1295-1302.
 * Wagner, G. J., Kanouse, D. E., Koegel, P., & Sullivan, G. (2003). Adherence to HIV antiretrovirals among persons with serious mental illness: AIDS Patient Care and STDs Vol 17(4) Apr 2003, 179-186.
 * Wagner, G. J., Kanouse, D. E., Koegel, P., & Sullivan, G. (2004). Correlates of HIV antiretroviral adherence in persons with serious mental illness: AIDS Care Vol 16(4) Apr 2004, 501-506.
 * Wagner, G. J., Remien, R. H., Carballo-Dieguez, A., & Dolezal, C. (2002). Correlates of adherence to combination antiretroviral therapy among members of HIV-positive mixed status couples: AIDS Care Vol 14(1) Feb 2002, 105-109.
 * Wagner, G. J., & Ryan, G. W. (2004). Relationship Between Routinization of Daily Behaviors and Medication Adherence in HIV-Positive Drug Users: AIDS Patient Care and STDs Vol 18(7) Jul 2004, 385-393.
 * Walkup, J., Sambamoorthi, U., & Crystal, S. (2001). Incidence and consistency of antiretroviral use among HIV-infected Medicaid beneficiaries with schizophrenia: Journal of Clinical Psychiatry Vol 62(3) Mar 2001, 174-178.
 * Walkup, J. T., Sambamoorthi, U., & Crystal, S. (2004). Use of Newer Antiretroviral Treatments Among HIV-Infected Medicaid Beneficiaries With Serious Mental Illness: Journal of Clinical Psychiatry Vol 65(9) Sep 2004, 1180-1189.
 * Wallach, I. (2007). A support group for people living with HIV and autonomy in management of retroviral treatment: Canadian Journal of Community Mental Health Vol 26(2) Fal 2007, 9-22.
 * Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., et al. (2002). Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection: New England Journal of Medicine Vol 346(26) Jun 2002, 2039-2046.
 * Wanyama, J., Castelnuovo, B., Wandera, B., Mwebaze, P., Kambugu, A., Bangsberg, D. R., et al. (2007). Belief in divine healing can be a barrier to antiretroviral therapy adherence in Uganda: AIDS Vol 21(11) Jul 2007, 1486-1487.
 * Ware, N. C., Wyatt, M. A., & Tugenberg, T. (2006). Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS: AIDS Care Vol 18(8) Nov 2006, 904-910.
 * Weidle, P. J., Wamai, N., Solberg, P., Liechty, C., Sendagala, S., Were, W., et al. (2006). Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda: Lancet Vol 368(9547) Nov 2006, 1587-1594.
 * Weiser, B., Philpott, S., Klimkait, T., Burger, H., Kitchen, C., Burgisser, P., et al. (2008). HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy: AIDS Vol 22(4) Feb 2008, 469-479.
 * Weiss, L., French, T., Finkelstein, R., Waters, M., Mukherjee, R., & Agins, B. (2003). HIV-related knowledge and adherence to HAART: AIDS Care Vol 15(5) Oct 2003, 673-679.
 * White, B. L., Wohl, D. A., Hays, R. D., Golin, C. E., Liu, H., Kiziah, C. N., et al. (2006). A Pilot Study of Health Beliefs and Attitudes Concerning Measures of Antiretroviral Adherence Among Prisoners Receiving Directly Observed Antiretroviral Therapy: AIDS Patient Care and STDs Vol 20(6) Jun 2006, 408-417.
 * White, K. L., Margot, N. A., Ly, J. K., Chen, J. M., Ray, A. S., Pavelko, M., et al. (2005). A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT: AIDS Vol 19(16) Nov 2005, 1751-1760.
 * Wicki, J., Germanier, Y., Sztajzel, R., & Burkhard, P. R. (2008). Brueghel syndrome as a new manifestation of HIV encephalopathy: European Neurology Vol 60(2) 2008, 107-108.
 * Wilkinson, M. J., Bain, B. J., Phelan, L., & Benzie, A. (2007). Increased haemoglobin A-sub-2 percentage in HIV infection: Disease or treatment: AIDS Vol 21(9) May 2007, 1207-1208.
 * Willard, S. (2006). Relationship of Emotional Intelligence and Adherence to Combination Antiretroviral Medications by Individuals Living With HIV Disease: JANAC: Journal of the Association of Nurses in AIDS Care Vol 17(2) Mar-Apr 2006, 16-26.
 * Williams, A. B., Fennie, K. P., Bova, C. A., Burgess, J. D., Danvers, K. A., & Dieckhaus, K. D. (2006). Home Visits to Improve Adherence to Highly Active Antiretroviral Therapy: A Randomized Controlled Trial: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 42(3) Jul 2006, 314-321.
 * Williams, K. R. (2003). Evaluation of the cognitive functioning of patients undergoing combination therapy for the treatment of chronic hepatitis C. Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Wilson, D. P., Kahn, J., Blower, S. M., & Singer, B. H. (2006). Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: The effect of the urban-rural divide: PNAS Proceedings of the National Academy of Sciences of the United States of America Vol 103(38) Sep 2006, 14228-14233.
 * Witteveen, E., & van Ameijden, E. J. C. (2002). Drug users and HIV-combination therapy (HAART): Factors which impede or facilitate adherence: Substance Use & Misuse Vol 37(14) Dec 2002, 1905-1925.
 * Wolbers, M., Opravil, M., von Wyl, V., Hirschel, B., Furrer, H., Cavassini, M., et al. (2007). Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: The Swiss HIV Cohort Study: Journal of Neurology, Neurosurgery & Psychiatry Vol 78(11) Nov 2007, 2201-2207.
 * Wolfe, W. R., Weiser, S. D., Bangsberg, D. R., Thior, I., Makhema, J. M., Dickinson, D. B., et al. (2006). Effects of HIV-related stigma among an early sample of patients receiving antiretroviral therapy in Botswana: AIDS Care Vol 18(8) Nov 2006, 931-933.
 * Wood, E., Hogg, R. S., Lima, V. D., Kerr, T., Yip, B., Marshall, B. D. L., et al. (2008). Highly active antiretroviral therapy and survival in HIV-infected injection drug users: JAMA: Journal of the American Medical Association Vol 300(5) Aug 2008, 550-554.
 * Wood, E., Montaner, J. S. G., Braitstein, P., Yip, B., Schecter, M. T., O'Shaughnessy, M. V., et al. (2004). Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: Implications for drug policy and public health: International Journal of Drug Policy Vol 15(2) Apr 2004, 133-138.
 * Wood, R. (2005). Antiretroviral therapy. New York, NY: Cambridge University Press.
 * Wynn, G. H., Cozza, K. L., Zapor, M. J., Wortmann, G. W., & Armstrong, S. C. (2005). Antiretrovirals, Part III: Antiretrovirals and Drugs of Abuse: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 46(1) Jan-Feb 2005, 79-87.
 * Wynn, G. H., Zapor, M. J., Smith, B. H., Wortmann, G., Oesterheld, J. R., Armstrong, S. C., et al. (2004). Antiretrovirals, part 1: Overview, history, and focus on protease inhibitors: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 45(3) May-Jun 2004, 262-270.
 * Yang, J. (2008). Mechanisms of IFN-gamma mediated anti-VSV response in neurons. Dissertation Abstracts International: Section B: The Sciences and Engineering.
 * Yun, L. W. H., Maravi, M., Kobayashi, J. S., Barton, P. L., & Davidson, A. J. (2005). Antidepressant Treatment Improves Adherence to Antiretroviral Therapy Among Depressed HIV-Infected Patients: JAIDS Journal of Acquired Immune Deficiency Syndromes Vol 38(4) Apr 2005, 432-438.
 * Zachariah, R., Fitzgerald, M., Massaquoi, M., Pasulani, O., Arnould, L., Makombe, S., et al. (2006). Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi: AIDS Vol 20(18) Nov 2006, 2355-2360.
 * Zapor, M. J., Cozza, K. L., Wynn, G. H., Wortmann, G. W., & Armstrong, S. C. (2004). Antiretrovirals, Part II: Focus on Non-Protease Inhibitor Antiretrovirals (NRTIs, NNRTIs, and Fusion Inhibitors): Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 45(6) Dec 2004, 524-535.
 * Zinkernagel, C., Ledergerber, B., Battegay, M., Cone, R. W., Vernazza, P., Hirschel, B., et al. (1999). Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy: AIDS Vol 13(12) Aug 1999, 1587-1589.

Papers

 * Google Scholar